≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Idiopathic hypercalciuria

Endpoint Browser PheWeb

E4_IDIOPATHIC_HYPERCALCIURIA

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — E83.58
  • Cause of death: ICD-10 — E83.58

2 out of 7 registries used, show all original rules.

213

4. Check minimum number of events

None

213

5. Include endpoints

None

213

6. Filter based on genotype QC (FinnGen only)

208

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 208 111 97
Unadjusted period prevalence (%) 0.04 0.04 0.04
Median age at first event (years) 55.15 56.98 53.06

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
213
Matched controls
2130
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E83.58
ICD-10 Finland
Idiopathic hypercalciuria
+∞
308.4
213
*
N20.1
ICD-10 Finland
Calculus of ureter
26.9
83.0
62
32
N20.0
ICD-10 Finland
Calculus of kidney
35.0
76.7
51
19
N20.9
ICD-10 Finland
Urinary calculus, unspecified
33.2
69.9
47
18
KH1AD
NOMESCO Finland
CT of urinary organs
22.6
57.6
45
25
C03AA03
ATC
hydrochlorothiazide; oral
9.0
38.5
55
79
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
8.0
31.9
50
79
M05BA04
ATC
alendronic acid; oral
8.6
31.9
46
66
KAT00
NOMESCO Finland
Extracorporeal shock wave lithotripsy of pelvis of kidney
45.0
25.7
31
8
C03EA01
ATC
hydrochlorothiazide and potassium-sparing agents; oral
5.3
25.1
63
156
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
30.0
23.4
31
12
UKC02
NOMESCO Finland
Cystoscopy
4.3
18.5
58
169
E21.0
ICD-10 Finland
Primary hyperparathyroidism
18.7
16.5
25
15
KAE12
NOMESCO Finland
Retrograde ureteronephroscopic lithotripsy in pelvis of kidney
61.2
15.0
17
*
E83.50
ICD-10 Finland
Hypercalcemia
23.1
15.0
21
10
M81.5
ICD-10 Finland
Idiopathic osteoporosis
86.2
14.8
16
*
KH1AA
NOMESCO Finland
Urinary tract X-ray examination without contrast
18.2
13.3
20
12
N20.2
ICD-10 Finland
Calculus of kidney with calculus of ureter
34.4
12.8
16
5
E21.3
ICD-10 Finland
Hyperparathyroidism, unspecified
26.2
12.7
17
7
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
19.5
12.3
18
10
KBE12
NOMESCO Finland
Transluminal endoscopic extraction of calculus of ureter
22.9
12.2
17
8
KBV12
NOMESCO Finland
Transluminal endoscopic removal of stent from ureter
20.4
11.8
17
9
BBA30
NOMESCO Finland
Excision of lesion of parathyroid gland
24.6
11.8
16
7
M81.9
ICD-10 Finland
Osteoporosis, unspecified
8.3
10.2
22
29
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
4.3
9.5
26
67
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.5
9.3
91
492
L95
ICPC
Osteoporosis
5.2
9.3
20
42
M80.9
ICD-10 Finland
Unspecified osteoporosis with pathological fracture
16.5
9.2
14
9
R31
ICD-10 Finland
Unspecified haematuria
3.6
9.1
33
104
KBT00
NOMESCO Finland
Extracorporeal shock wave lithotripsy of ureter
28.8
8.6
11
*
M05BX04
ATC
denosumab; parenteral
4.1
8.3
24
64
KBV10
NOMESCO Finland
Removal of stent from ureter
34.8
8.1
10
*
M80.5
ICD-10 Finland
Idiopathic osteoporosis with pathological fracture
34.8
8.1
10
*
N21.0
ICD-10 Finland
Calculus in bladder
19.2
7.7
11
6
KCE02
NOMESCO Finland
Transluminal endoscopic extraction of calculus from bladder
26.1
7.6
10
*
E83.59
ICD-10 Finland
Other disorders of calcium metabolism
82.9
7.5
8
*
M81.8
ICD-10 Finland
Other osteoporosis
20.9
7.2
10
5
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.1
6.6
88
526
M81.0
ICD-10 Finland
Postmenopausal osteoporosis
6.9
6.5
15
23
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
7.4
6.3
14
20
M821, E8358,
ICD-10 Finland
+∞
6.3
6
*
XQ800
NOMESCO Finland
Prick test
3.2
6.2
25
84
D86.0
ICD-10 Finland
Sarcoidosis of lung
7.6
6.0
13
18

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Calcium [Moles/time] in 24 hour Urine
14637-3 [3010838]
3.8e+00
4.5e+00
—
—
1.0e+50
4.8e+00
4.4e+00
cases:12.74%
controls:0.33%
cases:19.81%
controls:0.28%
—
—
—
—
cases:2.36%
controls:0.00%
cases:25.36%
controls:0.29%
cases:30.77%
controls:0.52%
27
7
185
2110
42
6
170
2111
—
—
5
0
207
2116
53
6
156
2073
60
10
135
1910
hydrochlorothiazide; oral
C03AA03 [21601466]
1.9e+00
2.7e+00
1.9e+00
1.0e+50
3.7e+00
3.4e+00
2.9e+00
cases:11.32%
controls:1.94%
cases:16.04%
controls:1.32%
cases:2.83%
controls:0.43%
cases:14.62%
controls:0.00%
cases:13.68%
controls:0.38%
cases:33.49%
controls:1.64%
cases:32.82%
controls:2.66%
24
41
188
2076
34
28
178
2089
6
9
206
2108
31
0
181
2117
29
8
183
2108
70
34
139
2045
64
51
131
1869
Outpatient Visit
OP [9202]
1.0e+00
1.2e+00
8.2e-01
6.8e+00
1.3e+00
1.5e+00
1.4e+00
cases:85.85%
controls:68.16%
cases:75.94%
controls:47.85%
cases:21.23%
controls:10.58%
cases:71.70%
controls:0.28%
cases:29.72%
controls:10.73%
cases:79.90%
controls:46.42%
cases:92.82%
controls:75.73%
182
1443
30
674
161
1013
51
1104
45
224
167
1893
152
6
60
2111
63
227
149
1889
167
965
42
1114
181
1454
14
466
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
1.3e+00
2.4e+00
4.0e+00
—
2.4e+00
2.0e+00
1.7e+00
cases:20.28%
controls:6.61%
cases:27.36%
controls:3.31%
cases:26.42%
controls:0.66%
—
—
cases:7.08%
controls:0.66%
cases:27.27%
controls:5.05%
cases:44.62%
controls:12.45%
43
140
169
1977
58
70
154
2047
56
14
156
2103
—
15
14
197
2102
57
105
152
1974
87
239
108
1681
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
1.5e+00
1.8e+00
4.1e+00
—
2.7e+00
1.9e+00
1.6e+00
cases:20.75%
controls:5.57%
cases:18.87%
controls:3.68%
cases:19.34%
controls:0.38%
—
—
cases:5.19%
controls:0.38%
cases:20.10%
controls:3.46%
cases:39.49%
controls:11.51%
44
118
168
1999
40
78
172
2039
41
8
171
2109
—
11
8
201
2108
42
72
167
2007
77
221
118
1699
Endocrinology
46 [38004485]
1.5e+00
2.2e+00
—
—
3.6e+00
3.7e+00
2.5e+00
cases:15.57%
controls:4.06%
cases:16.04%
controls:2.13%
—
—
—
—
cases:12.74%
controls:0.38%
cases:44.50%
controls:1.97%
cases:33.85%
controls:3.96%
33
86
179
2031
34
45
178
2072
—
—
27
8
185
2108
93
41
116
2038
66
76
129
1844
pH of Serum or Plasma
2753-2 [3018418]
1.3e+00
2.2e+00
4.0e+00
—
2.3e+00
2.0e+00
1.4e+00
cases:11.79%
controls:3.50%
cases:16.04%
controls:2.03%
cases:16.04%
controls:0.33%
—
—
cases:4.72%
controls:0.47%
cases:15.79%
controls:2.55%
cases:23.08%
controls:6.88%
25
74
187
2043
34
43
178
2074
34
7
178
2110
—
10
10
202
2106
33
53
176
2026
45
132
150
1788
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1.3e+00
2.3e+00
3.7e+00
—
2.3e+00
1.8e+00
1.5e+00
cases:18.40%
controls:6.00%
cases:22.17%
controls:2.83%
cases:20.75%
controls:0.61%
—
—
cases:6.13%
controls:0.66%
cases:22.97%
controls:4.57%
cases:35.38%
controls:10.52%
39
127
173
1990
47
60
165
2057
44
13
168
2104
—
13
14
199
2102
48
95
161
1984
69
202
126
1718
Urology
34 [38004474]
1.6e+00
2.4e+00
2.5e+00
—
2.1e+00
2.1e+00
1.6e+00
cases:17.92%
controls:4.30%
cases:20.28%
controls:2.31%
cases:3.77%
controls:0.33%
—
—
cases:4.25%
controls:0.52%
cases:11.96%
controls:1.59%
cases:18.46%
controls:4.48%
38
91
174
2026
43
49
169
2068
8
7
204
2110
—
9
11
203
2105
25
33
184
2046
36
86
159
1834
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
2.8e+00
3.6e+00
—
—
—
3.2e+00
2.5e+00
cases:14.62%
controls:1.04%
cases:15.57%
controls:0.52%
—
—
—
—
—
—
cases:13.88%
controls:0.63%
cases:20.00%
controls:2.08%
31
22
181
2095
33
11
179
2106
—
—
—
29
13
180
2066
39
40
156
1880
hydrochlorothiazide and potassium-sparing agents
C03EA01 [21601543]
1.2e+00
1.9e+00
—
1.0e+50
2.6e+00
2.6e+00
2.5e+00
cases:6.60%
controls:2.13%
cases:9.43%
controls:1.61%
—
—
cases:4.25%
controls:0.00%
cases:5.66%
controls:0.43%
cases:16.75%
controls:1.44%
cases:18.46%
controls:1.77%
14
45
198
2072
20
34
192
2083
—
9
0
203
2117
12
9
200
2107
35
30
174
2049
36
34
159
1886
Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma
2742-5 [3034780]
2.4e+00
2.6e+00
1.0e+50
—
—
2.7e+00
2.3e+00
cases:5.66%
controls:0.57%
cases:5.66%
controls:0.43%
cases:6.13%
controls:0.00%
—
—
—
—
cases:4.31%
controls:0.29%
cases:7.69%
controls:0.83%
12
12
200
2105
12
9
200
2108
13
0
199
2117
—
—
9
6
200
2073
15
16
180
1904
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
2.0e+00
2.8e+00
—
—
2.3e+00
2.3e+00
2.0e+00
cases:11.32%
controls:1.65%
cases:12.26%
controls:0.80%
—
—
—
—
cases:2.36%
controls:0.24%
cases:10.05%
controls:1.06%
cases:19.49%
controls:3.28%
24
35
188
2082
26
17
186
2100
—
—
5
5
207
2111
21
22
188
2057
38
63
157
1857
Nephrology
39 [38004479]
1.0e+00
1.8e+00
—
—
2.9e+00
2.3e+00
2.2e+00
cases:2.83%
controls:1.04%
cases:4.25%
controls:0.76%
—
—
—
—
cases:4.72%
controls:0.28%
cases:9.57%
controls:1.01%
cases:8.72%
controls:1.04%
6
22
206
2095
9
16
203
2101
—
—
10
6
202
2110
20
21
189
2058
17
20
178
1900
alendronic acid; oral
M05BA04 [21604152]
2.4e+00
2.0e+00
—
—
—
2.2e+00
2.0e+00
cases:7.55%
controls:0.71%
cases:4.72%
controls:0.66%
—
—
—
—
—
—
cases:6.22%
controls:0.72%
cases:6.67%
controls:0.94%
16
15
196
2102
10
14
202
2103
—
—
—
13
15
196
2064
13
18
182
1902
pH of Specimen
17433-4 [3019225]
1.5e+00
2.4e+00
—
—
—
2.0e+00
2.1e+00
cases:5.66%
controls:1.37%
cases:6.13%
controls:0.57%
—
—
—
—
—
—
cases:6.70%
controls:0.96%
cases:12.31%
controls:1.77%
12
29
200
2088
13
12
199
2105
—
—
—
14
20
195
2059
24
34
171
1886
Lysozyme [Mass/volume] in Serum or Plasma
2589-0 [3012110]
2.7e+00
—
1.0e+50
—
—
2.7e+00
2.4e+00
cases:4.72%
controls:0.33%
—
—
cases:4.72%
controls:0.00%
—
—
—
—
cases:4.31%
controls:0.29%
cases:6.15%
controls:0.57%
10
7
202
2110
—
10
0
202
2117
—
—
9
6
200
2073
12
11
183
1909
Osteoporosis, unspecified
M81.9 [45591963]
2.2e+00
—
—
1.0e+50
—
2.7e+00
2.2e+00
cases:2.83%
controls:0.33%
—
—
—
—
cases:4.25%
controls:0.00%
—
—
cases:4.31%
controls:0.29%
cases:4.10%
controls:0.47%
6
7
206
2110
—
—
9
0
203
2117
—
9
6
200
2073
8
9
187
1911
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
8.8e-01
1.7e+00
2.7e+00
—
—
1.5e+00
1.1e+00
cases:8.96%
controls:3.92%
cases:10.38%
controls:2.17%
cases:5.19%
controls:0.38%
—
—
—
—
cases:9.57%
controls:2.36%
cases:18.97%
controls:7.50%
19
83
193
2034
22
46
190
2071
11
8
201
2109
—
—
20
49
189
2030
37
144
158
1776
Calculus of kidney
N20.0 [45567830]
3.6e+00
—
—
1.0e+50
—
—
3.2e+00
cases:9.43%
controls:0.28%
—
—
—
—
cases:5.19%
controls:0.00%
—
—
—
—
cases:9.23%
controls:0.42%
20
6
192
2111
—
—
11
0
201
2117
—
—
18
8
177
1912
Pharmacy visit
OMOP4822462 [581458]
1.3e+00
1.0e+00
4.1e-01
2.9e+00
6.5e-01
1.3e+00
1.5e+00
cases:98.11%
controls:93.48%
cases:92.92%
controls:82.66%
cases:51.42%
controls:41.28%
cases:26.42%
controls:1.89%
cases:60.85%
controls:44.75%
cases:95.22%
controls:83.93%
cases:98.97%
controls:95.52%
208
1979
4
138
197
1750
15
367
109
874
103
1243
56
40
156
2077
129
947
83
1169
199
1745
10
334
193
1834
2
86
Internal Medicine
11 [38004456]
6.3e-01
9.0e-01
7.0e-01
—
2.0e+00
1.4e+00
9.7e-01
cases:31.13%
controls:19.46%
cases:17.92%
controls:8.17%
cases:2.36%
controls:1.18%
—
—
cases:7.55%
controls:1.04%
cases:26.32%
controls:8.23%
cases:33.85%
controls:16.30%
66
412
146
1705
38
173
174
1944
5
25
207
2092
—
16
22
196
2094
55
171
154
1908
66
313
129
1607
Supplier / Service Provider
OMOP5117446 [33004]
-5.5e-01
-3.5e-01
—
—
—
2.8e+00
3.1e+00
cases:16.51%
controls:25.60%
cases:5.66%
controls:7.84%
—
—
—
—
—
—
cases:7.18%
controls:0.48%
cases:15.38%
controls:0.83%
35
542
177
1575
12
166
200
1951
—
—
—
15
10
194
2069
30
16
165
1904
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
7.6e-01
1.5e+00
2.7e+00
—
—
1.6e+00
5.3e-01
cases:4.72%
controls:2.27%
cases:5.19%
controls:1.18%
cases:4.25%
controls:0.28%
—
—
—
—
cases:5.26%
controls:1.15%
cases:5.64%
controls:3.39%
10
48
202
2069
11
25
201
2092
9
6
203
2111
—
—
11
24
198
2055
11
65
184
1855
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6.1e-01
1.1e+00
2.2e+00
—
4.4e-01
1.0e+00
8.7e-01
cases:25.00%
controls:15.30%
cases:24.06%
controls:9.54%
cases:13.21%
controls:1.70%
—
—
cases:2.83%
controls:1.84%
cases:22.01%
controls:9.43%
cases:43.08%
controls:24.01%
53
324
159
1793
51
202
161
1915
28
36
184
2081
—
6
39
206
2077
46
196
163
1883
84
461
111
1459
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
3.3e-01
7.1e-01
2.3e+00
—
1.2e+00
9.0e-01
6.2e-01
cases:31.60%
controls:24.89%
cases:31.13%
controls:18.19%
cases:21.23%
controls:2.74%
—
—
cases:10.85%
controls:3.45%
cases:36.84%
controls:19.14%
cases:59.49%
controls:44.22%
67
527
145
1590
66
385
146
1732
45
58
167
2059
—
23
73
189
2043
77
398
132
1681
116
849
79
1071
Other and unspecified abdominal pain
R10.4 [45568113]
1.1e+00
2.0e+00
—
—
-1.0e+50
1.5e+00
1.2e+00
cases:12.26%
controls:4.44%
cases:6.13%
controls:0.90%
—
—
—
—
cases:0.00%
controls:0.24%
cases:5.74%
controls:1.39%
cases:14.87%
controls:5.21%
26
94
186
2023
13
19
199
2098
—
—
0
5
212
2111
12
29
197
2050
29
100
166
1820
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
3.1e-01
7.0e-01
2.2e+00
—
1.3e+00
8.6e-01
6.0e-01
cases:31.60%
controls:25.27%
cases:31.13%
controls:18.38%
cases:21.23%
controls:2.88%
—
—
cases:10.85%
controls:3.31%
cases:36.36%
controls:19.48%
cases:59.49%
controls:44.58%
67
535
145
1582
66
389
146
1728
45
61
167
2056
—
23
70
189
2046
76
405
133
1674
116
856
79
1064
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
6.0e-01
1.1e+00
2.1e+00
—
1.1e+00
8.7e-01
7.1e-01
cases:23.11%
controls:14.12%
cases:18.40%
controls:7.09%
cases:7.55%
controls:0.99%
—
—
cases:3.30%
controls:1.13%
cases:17.70%
controls:8.27%
cases:37.95%
controls:23.13%
49
299
163
1818
39
150
173
1967
16
21
196
2096
—
7
24
205
2092
37
172
172
1907
74
444
121
1476
Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]
2.2e+00
—
—
1.0e+50
—
—
3.0e+00
cases:5.66%
controls:0.66%
—
—
—
—
cases:7.08%
controls:0.00%
—
—
—
—
cases:11.28%
controls:0.63%
12
14
200
2103
—
—
15
0
197
2117
—
—
22
12
173
1908
Laboratory Visit
OMOP4822461 [32036]
2.6e-01
3.8e-01
1.7e+00
2.5e+00
1.1e+00
4.0e-01
2.3e-01
cases:39.62%
controls:33.63%
cases:41.04%
controls:32.26%
cases:34.43%
controls:8.83%
cases:4.25%
controls:0.38%
cases:23.11%
controls:9.50%
cases:44.98%
controls:35.35%
cases:65.13%
controls:59.84%
84
712
128
1405
87
683
125
1434
73
187
139
1930
9
8
203
2109
49
201
163
1915
94
735
115
1344
127
1149
68
771
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5.1e-01
1.1e+00
2.9e+00
—
—
9.4e-01
3.4e-01
cases:10.38%
controls:6.52%
cases:9.91%
controls:3.45%
cases:5.66%
controls:0.33%
—
—
—
—
cases:9.09%
controls:3.75%
cases:18.97%
controls:14.27%
22
138
190
1979
21
73
191
2044
12
7
200
2110
—
—
19
78
190
2001
37
274
158
1646
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
4.8e-01
1.1e+00
2.9e+00
—
—
9.3e-01
3.2e-01
cases:10.38%
controls:6.66%
cases:9.91%
controls:3.59%
cases:5.66%
controls:0.33%
—
—
—
—
cases:9.09%
controls:3.80%
cases:18.97%
controls:14.53%
22
141
190
1976
21
76
191
2041
12
7
200
2110
—
—
19
79
190
2000
37
279
158
1641
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
4.9e-01
1.1e+00
2.9e+00
—
—
9.4e-01
3.2e-01
cases:10.85%
controls:6.94%
cases:9.91%
controls:3.68%
cases:5.66%
controls:0.33%
—
—
—
—
cases:9.09%
controls:3.75%
cases:18.97%
controls:14.53%
23
147
189
1970
21
78
191
2039
12
7
200
2110
—
—
19
78
190
2001
37
279
158
1641
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
3.2e-01
8.4e-01
2.7e+00
—
—
1.3e+00
8.5e-01
cases:8.49%
controls:6.33%
cases:7.55%
controls:3.40%
cases:7.55%
controls:0.52%
—
—
—
—
cases:11.00%
controls:3.42%
cases:22.05%
controls:10.83%
18
134
194
1983
16
72
196
2045
16
11
196
2106
—
—
23
71
186
2008
43
208
152
1712
Cystoscopy
UKC02 [2001306005]
2.2e+00
2.5e+00
—
—
—
—
9.6e-01
cases:9.43%
controls:1.09%
cases:5.19%
controls:0.43%
—
—
—
—
—
—
—
—
cases:3.08%
controls:1.20%
20
23
192
2094
11
9
201
2108
—
—
—
—
6
23
189
1897
pH of Urine
2756-5 [3015736]
1.0e-01
1.0e+00
2.7e+00
—
—
1.0e+00
3.2e-01
cases:6.13%
controls:5.57%
cases:7.08%
controls:2.60%
cases:4.72%
controls:0.33%
—
—
—
—
cases:7.18%
controls:2.74%
cases:14.87%
controls:11.30%
13
118
199
1999
15
55
197
2062
10
7
202
2110
—
—
15
57
194
2022
29
217
166
1703
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
4.6e-01
1.1e+00
2.0e+00
—
—
8.0e-01
7.3e-01
cases:18.40%
controls:12.42%
cases:15.57%
controls:6.05%
cases:5.19%
controls:0.71%
—
—
—
—
cases:12.44%
controls:6.01%
cases:30.77%
controls:17.60%
39
263
173
1854
33
128
179
1989
11
15
201
2102
—
—
26
125
183
1954
60
338
135
1582
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
2.9e-01
6.9e-01
2.2e+00
—
9.8e-01
7.0e-01
4.9e-01
cases:33.96%
controls:27.78%
cases:35.38%
controls:21.54%
cases:25.47%
controls:3.54%
—
—
cases:10.38%
controls:4.16%
cases:37.32%
controls:22.80%
cases:61.03%
controls:48.96%
72
588
140
1529
75
456
137
1661
54
75
158
2042
—
22
88
190
2028
78
474
131
1605
119
940
76
980
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
5.6e-01
1.3e+00
2.5e+00
—
—
7.9e-01
7.5e-01
cases:8.49%
controls:5.05%
cases:8.02%
controls:2.27%
cases:3.30%
controls:0.28%
—
—
—
—
cases:5.26%
controls:2.45%
cases:15.38%
controls:7.92%
18
107
194
2010
17
48
195
2069
7
6
205
2111
—
—
11
51
198
2028
30
152
165
1768
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
5.5e-01
1.3e+00
2.2e+00
—
—
8.0e-01
8.4e-01
cases:7.08%
controls:4.20%
cases:7.08%
controls:1.98%
cases:3.30%
controls:0.38%
—
—
—
—
cases:4.78%
controls:2.21%
cases:13.85%
controls:6.46%
15
89
197
2028
15
42
197
2075
7
8
205
2109
—
—
10
46
199
2033
27
124
168
1796
potassium chloride; oral
A12BA01 [21600877]
—
2.1e+00
—
—
—
2.1e+00
1.0e+00
—
—
cases:4.25%
controls:0.52%
—
—
—
—
—
—
cases:5.26%
controls:0.67%
cases:5.13%
controls:1.93%
—
9
11
203
2106
—
—
—
11
14
198
2065
10
37
185
1883
Pulmonary Disease
29 [38004472]
1.0e+00
1.2e+00
1.4e+00
—
1.3e+00
1.0e+00
9.3e-01
cases:16.98%
controls:6.90%
cases:12.74%
controls:4.06%
cases:2.36%
controls:0.61%
—
—
cases:2.83%
controls:0.80%
cases:10.05%
controls:3.94%
cases:18.97%
controls:8.44%
36
146
176
1971
27
86
185
2031
5
13
207
2104
—
6
17
206
2099
21
82
188
1997
37
162
158
1758
Case Management Agency
251B00000X [38004193]
8.7e-02
1.5e-01
2.5e-01
3.4e+00
5.3e-01
2.8e-01
1.6e-01
cases:60.85%
controls:58.76%
cases:57.08%
controls:53.33%
cases:23.11%
controls:19.04%
cases:24.53%
controls:1.09%
cases:30.19%
controls:20.23%
cases:63.64%
controls:57.05%
cases:82.56%
controls:80.21%
129
1244
83
873
121
1129
91
988
49
403
163
1714
52
23
160
2094
64
428
148
1688
133
1186
76
893
161
1540
34
380
Leukocytes [#/volume] in Urine
30405-5 [3018095]
6.7e-01
1.2e+00
2.3e+00
—
—
8.5e-01
6.8e-01
cases:8.49%
controls:4.53%
cases:7.55%
controls:2.31%
cases:3.77%
controls:0.38%
—
—
—
—
cases:5.74%
controls:2.55%
cases:14.36%
controls:7.81%
18
96
194
2021
16
49
196
2068
8
8
204
2109
—
—
12
53
197
2026
28
150
167
1770
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
4.8e-01
5.0e-01
2.0e+00
—
1.5e+00
5.2e-01
5.2e-01
cases:23.58%
controls:16.01%
cases:14.62%
controls:9.45%
cases:7.08%
controls:1.04%
—
—
cases:5.19%
controls:1.23%
cases:15.31%
controls:9.72%
cases:36.92%
controls:25.78%
50
339
162
1778
31
200
181
1917
15
22
197
2095
—
11
26
201
2090
32
202
177
1877
72
495
123
1425
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
5.2e-01
1.1e+00
2.3e+00
—
—
8.6e-01
3.3e-01
cases:9.43%
controls:5.86%
cases:8.02%
controls:2.88%
cases:3.30%
controls:0.33%
—
—
—
—
cases:7.18%
controls:3.17%
cases:14.87%
controls:11.20%
20
124
192
1993
17
61
195
2056
7
7
205
2110
—
—
15
66
194
2013
29
215
166
1705
Calculus of ureter
N20.1 [45582395]
—
1.0e+50
1.0e+50
—
1.0e+50
—
3.3e+00
—
—
cases:11.32%
controls:0.00%
cases:2.36%
controls:0.00%
—
—
cases:2.83%
controls:0.00%
—
—
cases:8.21%
controls:0.31%
—
24
0
188
2117
5
0
207
2117
—
6
0
206
2116
—
16
6
179
1914
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
2.0e-01
5.6e-01
1.8e+00
—
8.8e-01
6.6e-01
5.3e-01
cases:21.23%
controls:18.04%
cases:22.64%
controls:14.31%
cases:13.68%
controls:2.65%
—
—
cases:6.60%
controls:2.84%
cases:25.84%
controls:15.20%
cases:45.64%
controls:32.97%
45
382
167
1735
48
303
164
1814
29
56
183
2061
—
14
60
198
2056
54
316
155
1763
89
633
106
1287
CT of urinary organs
KH1AD [2001306328]
—
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.15%
controls:0.36%
—
—
—
—
—
—
12
7
183
1913
Pain localized to other parts of lower abdomen
R10.3 [45534426]
8.0e-01
—
—
—
—
2.6e+00
9.0e-01
cases:5.19%
controls:2.41%
—
—
—
—
—
—
—
—
cases:3.83%
controls:0.29%
cases:6.15%
controls:2.60%
11
51
201
2066
—
—
—
—
8
6
201
2073
12
50
183
1870
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
1.0e+00
1.6e+00
—
—
—
4.5e-01
5.9e-01
cases:9.43%
controls:3.64%
cases:8.02%
controls:1.79%
—
—
—
—
—
—
cases:2.39%
controls:1.54%
cases:12.31%
controls:7.19%
20
77
192
2040
17
38
195
2079
—
—
—
5
32
204
2047
24
138
171
1782
Emergency Room Visit
ER [9203]
6.7e-01
1.0e+00
1.3e+00
—
—
6.0e-01
6.4e-01
cases:49.06%
controls:33.02%
cases:25.00%
controls:10.72%
cases:4.25%
controls:1.23%
—
—
—
—
cases:16.27%
controls:9.62%
cases:41.54%
controls:27.19%
104
699
108
1418
53
227
159
1890
9
26
203
2091
—
—
34
200
175
1879
81
522
114
1398
Neck ultrasound examination
EP1AE [2001302284]
2.3e+00
—
—
—
—
—
1.7e+00
cases:2.83%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:2.56%
controls:0.47%
6
6
206
2111
—
—
—
—
—
5
9
190
1911
Parathyrin.intact [Moles/volume] in Serum or Plasma
14866-8 [3010566]
—
—
1.0e+50
—
—
—
2.3e+00
—
—
—
—
cases:3.30%
controls:0.00%
—
—
—
—
—
—
cases:4.10%
controls:0.42%
—
—
7
0
205
2117
—
—
—
8
8
187
1912
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
3.6e-01
5.4e-01
1.6e+00
—
—
7.2e-01
6.5e-01
cases:11.79%
controls:8.55%
cases:7.55%
controls:4.53%
cases:4.25%
controls:0.85%
—
—
—
—
cases:10.05%
controls:5.15%
cases:21.54%
controls:12.50%
25
181
187
1936
16
96
196
2021
9
18
203
2099
—
—
21
107
188
1972
42
240
153
1680
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
2.6e-01
5.6e-01
1.7e+00
—
2.2e-01
3.0e-01
2.6e-01
cases:28.77%
controls:23.76%
cases:26.42%
controls:16.96%
cases:14.62%
controls:3.16%
—
—
cases:4.25%
controls:3.45%
cases:23.44%
controls:18.57%
cases:46.67%
controls:40.26%
61
503
151
1614
56
359
156
1758
31
67
181
2050
—
9
73
203
2043
49
386
160
1693
91
773
104
1147
Metatarsalgia
M77.4 [45601544]
2.2e+00
—
—
—
—
—
—
cases:2.83%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
206
2110
—
—
—
—
—
—
Hip X-ray examination
NF1AA [2001307894]
1.0e+00
2.2e+00
—
—
—
—
1.2e+00
cases:2.36%
controls:0.85%
cases:2.83%
controls:0.33%
—
—
—
—
—
—
—
—
cases:2.56%
controls:0.78%
5
18
207
2099
6
7
206
2110
—
—
—
—
5
15
190
1905
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
4.0e-01
5.3e-01
2.1e+00
—
1.2e+00
5.8e-01
4.7e-01
cases:27.83%
controls:20.60%
cases:20.28%
controls:12.99%
cases:8.96%
controls:1.23%
—
—
cases:5.66%
controls:1.75%
cases:21.53%
controls:13.28%
cases:46.67%
controls:35.42%
59
436
153
1681
43
275
169
1842
19
26
193
2091
—
12
37
200
2079
45
276
164
1803
91
680
104
1240
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
1.2e+00
2.0e+00
—
—
—
—
6.9e-01
cases:2.83%
controls:0.85%
cases:2.83%
controls:0.38%
—
—
—
—
—
—
—
—
cases:3.08%
controls:1.56%
6
18
206
2099
6
8
206
2109
—
—
—
—
6
30
189
1890
Cystoscopic insertion of stent into ureter
KBV02 [2001305891]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.08%
controls:0.42%
—
—
—
—
—
—
6
8
189
1912
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
2.9e-01
5.9e-01
1.3e+00
—
—
7.4e-01
6.5e-01
cases:12.74%
controls:9.87%
cases:9.43%
controls:5.48%
cases:5.19%
controls:1.42%
—
—
—
—
cases:12.44%
controls:6.35%
cases:25.64%
controls:15.21%
27
209
185
1908
20
116
192
2001
11
30
201
2087
—
—
26
132
183
1947
50
292
145
1628
Osteoporosis
L95 [2002000714]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.10%
controls:0.63%
—
—
—
—
—
—
8
12
187
1908
calcium (different salts in combination); oral
A12AA20 [21600872]
1.0e+00
6.7e-01
—
—
3.1e-01
5.9e-01
8.5e-01
cases:19.81%
controls:7.98%
cases:11.79%
controls:6.42%
—
—
—
—
cases:2.36%
controls:1.75%
cases:11.48%
controls:6.69%
cases:18.97%
controls:9.06%
42
169
170
1948
25
136
187
1981
—
—
5
37
207
2079
24
139
185
1940
37
174
158
1746
s-atenolol; oral
C07AB11 [21601693]
1.9e+00
—
—
—
—
—
—
cases:3.30%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
7
11
205
2106
—
—
—
—
—
—
atenolol; oral, parenteral
C07AB03 [21601685]
1.9e+00
—
—
—
—
—
—
cases:3.30%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
7
11
205
2106
—
—
—
—
—
—
denosumab; parenteral
M05BX04 [21604169]
—
—
—
—
—
1.9e+00
1.6e+00
—
—
—
—
—
—
—
—
—
—
cases:3.35%
controls:0.53%
cases:4.10%
controls:0.89%
—
—
—
—
—
7
11
202
2068
8
17
187
1903
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.7e-01
6.3e-01
1.2e+00
—
2.1e-01
4.6e-01
4.0e-01
cases:28.30%
controls:23.15%
cases:24.53%
controls:14.79%
cases:8.96%
controls:2.79%
—
—
cases:3.77%
controls:3.07%
cases:22.49%
controls:15.54%
cases:49.23%
controls:39.48%
60
490
152
1627
52
313
160
1804
19
59
193
2058
—
8
65
204
2051
47
323
162
1756
96
758
99
1162
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
1.8e+00
—
—
—
—
—
6.5e-01
cases:4.25%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:2.56%
controls:1.35%
9
15
203
2102
—
—
—
—
—
5
26
190
1894
Low back symptom/complaint
L03 [2002000628]
-2.5e-01
1.8e+00
—
—
—
6.2e-01
3.2e-01
cases:2.36%
controls:3.02%
cases:4.72%
controls:0.80%
—
—
—
—
—
—
cases:2.39%
controls:1.30%
cases:8.21%
controls:6.09%
5
64
207
2053
10
17
202
2100
—
—
—
5
27
204
2052
16
117
179
1803
Hyperplasia of prostate
N40 [45563015]
6.5e-01
1.8e+00
—
—
—
1.4e+00
4.0e-01
cases:3.30%
controls:1.75%
cases:5.19%
controls:0.90%
—
—
—
—
—
—
cases:2.87%
controls:0.72%
cases:3.08%
controls:2.08%
7
37
205
2080
11
19
201
2098
—
—
—
6
15
203
2064
6
40
189
1880
Leiomyoma of uterus, unspecified
D25.9 [45542693]
1.8e+00
—
—
—
—
—
—
cases:3.30%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
7
12
205
2105
—
—
—
—
—
—
Urine symptom/complaint other
U07 [2002001142]
—
—
—
—
—
-1.0e+50
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
cases:3.59%
controls:0.63%
—
—
—
—
—
0
5
209
2074
7
12
188
1908
Malaise and fatigue
R53 [45553741]
5.9e-01
1.8e+00
—
—
—
—
6.8e-01
cases:3.77%
controls:2.13%
cases:3.77%
controls:0.66%
—
—
—
—
—
—
—
—
cases:6.67%
controls:3.49%
8
45
204
2072
8
14
204
2103
—
—
—
—
13
67
182
1853
Unspecified haematuria
R31 [45553726]
1.8e+00
2.3e+00
—
—
—
—
1.3e+00
cases:3.77%
controls:0.66%
cases:2.36%
controls:0.24%
—
—
—
—
—
—
—
—
cases:2.56%
controls:0.68%
8
14
204
2103
5
5
207
2112
—
—
—
—
5
13
190
1907
Complement C4 [Mass/volume] in Serum or Plasma
4498-2 [3017766]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.10%
controls:0.73%
—
—
—
—
—
—
8
14
187
1906
Complement C3 [Mass/volume] in Serum or Plasma
4485-9 [3000620]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.10%
controls:0.73%
—
—
—
—
—
—
8
14
187
1906
pimecrolimus
D11AH02 [21602339]
—
-1.0e+50
—
—
—
—
1.8e+00
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:4.10%
controls:0.73%
—
0
5
212
2112
—
—
—
—
8
14
187
1906
MCH [Entitic mass]
28539-5 [3035941]
3.2e-01
4.6e-01
1.8e+00
—
2.7e-01
3.5e-01
3.6e-01
cases:37.74%
controls:30.47%
cases:34.43%
controls:24.99%
cases:22.17%
controls:4.68%
—
—
cases:6.60%
controls:5.10%
cases:33.97%
controls:26.65%
cases:62.56%
controls:53.91%
80
645
132
1472
73
529
139
1588
47
99
165
2018
—
14
108
198
2008
71
554
138
1525
122
1035
73
885
General Surgery
2 [38004447]
7.1e-01
1.0e+00
—
—
—
4.9e-01
5.8e-01
cases:31.13%
controls:18.14%
cases:14.15%
controls:5.53%
—
—
—
—
—
—
cases:8.13%
controls:5.15%
cases:20.51%
controls:12.66%
66
384
146
1733
30
117
182
2000
—
—
—
17
107
192
1972
40
243
155
1677
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
3.2e-01
4.5e-01
1.7e+00
—
2.7e-01
3.4e-01
3.6e-01
cases:37.74%
controls:30.47%
cases:34.43%
controls:25.04%
cases:22.17%
controls:4.72%
—
—
cases:6.60%
controls:5.10%
cases:33.97%
controls:26.74%
cases:62.56%
controls:53.91%
80
645
132
1472
73
530
139
1587
47
100
165
2017
—
14
108
198
2008
71
556
138
1523
122
1035
73
885
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
3.2e-01
4.5e-01
1.7e+00
—
2.6e-01
3.6e-01
3.5e-01
cases:37.74%
controls:30.47%
cases:34.43%
controls:25.08%
cases:22.17%
controls:4.72%
—
—
cases:6.60%
controls:5.15%
cases:34.45%
controls:26.74%
cases:62.56%
controls:53.96%
80
645
132
1472
73
531
139
1586
47
100
165
2017
—
14
109
198
2007
72
556
137
1523
122
1036
73
884
Platelets [#/volume] in Blood
26515-7 [3007461]
3.3e-01
4.6e-01
1.7e+00
—
2.6e-01
3.2e-01
3.6e-01
cases:37.74%
controls:30.42%
cases:34.43%
controls:24.94%
cases:22.17%
controls:4.72%
—
—
cases:6.60%
controls:5.15%
cases:33.49%
controls:26.70%
cases:62.56%
controls:53.75%
80
644
132
1473
73
528
139
1589
47
100
165
2017
—
14
109
198
2007
70
555
139
1524
122
1032
73
888
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
3.2e-01
4.5e-01
1.7e+00
—
2.4e-01
3.6e-01
3.5e-01
cases:37.74%
controls:30.51%
cases:34.43%
controls:25.18%
cases:22.17%
controls:4.72%
—
—
cases:6.60%
controls:5.25%
cases:34.45%
controls:26.84%
cases:62.56%
controls:54.11%
80
646
132
1471
73
533
139
1584
47
100
165
2017
—
14
111
198
2005
72
558
137
1521
122
1039
73
881
Leukocytes [#/volume] in Blood
26464-8 [3010813]
3.2e-01
4.5e-01
1.7e+00
—
2.6e-01
3.5e-01
3.8e-01
cases:37.74%
controls:30.51%
cases:34.43%
controls:25.08%
cases:22.17%
controls:4.72%
—
—
cases:6.60%
controls:5.15%
cases:34.45%
controls:26.98%
cases:63.08%
controls:53.96%
80
646
132
1471
73
531
139
1586
47
100
165
2017
—
14
109
198
2007
72
561
137
1518
123
1036
72
884
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
3.2e-01
4.5e-01
1.7e+00
—
2.6e-01
3.4e-01
3.5e-01
cases:37.74%
controls:30.47%
cases:34.43%
controls:25.08%
cases:22.17%
controls:4.72%
—
—
cases:6.60%
controls:5.15%
cases:33.97%
controls:26.74%
cases:62.56%
controls:53.96%
80
645
132
1472
73
531
139
1586
47
100
165
2017
—
14
109
198
2007
71
556
138
1523
122
1036
73
884
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
—
—
—
—
—
1.7e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:2.39%
controls:0.43%
cases:6.15%
controls:1.15%
—
—
—
—
—
5
9
204
2070
12
22
183
1898
CBC panel - Blood by Automated count
58410-2 [40761511]
3.2e-01
4.9e-01
1.7e+00
—
4.3e-02
3.0e-01
3.5e-01
cases:33.02%
controls:26.26%
cases:26.42%
controls:18.00%
cases:12.26%
controls:2.46%
—
—
cases:3.30%
controls:3.17%
cases:23.44%
controls:18.52%
cases:51.79%
controls:42.97%
70
556
142
1561
56
381
156
1736
26
52
186
2065
—
7
67
205
2049
49
385
160
1694
101
825
94
1095
combinations of corticosteroids
D07AB30 [21602118]
8.0e-01
5.0e-01
—
—
-1.0e+50
6.0e-01
8.8e-01
cases:18.87%
controls:9.49%
cases:5.66%
controls:3.50%
—
—
—
—
cases:0.00%
controls:0.33%
cases:6.22%
controls:3.51%
cases:21.54%
controls:10.21%
40
201
172
1916
12
74
200
2043
—
—
0
7
212
2109
13
73
196
2006
42
196
153
1724
combinations of corticosteroids
D07XB30 [21602188]
8.0e-01
5.0e-01
—
—
-1.0e+50
6.0e-01
8.8e-01
cases:18.87%
controls:9.49%
cases:5.66%
controls:3.50%
—
—
—
—
cases:0.00%
controls:0.33%
cases:6.22%
controls:3.51%
cases:21.54%
controls:10.21%
40
201
172
1916
12
74
200
2043
—
—
0
7
212
2109
13
73
196
2006
42
196
153
1724
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]
6.9e-01
1.6e+00
—
—
—
—
7.9e-01
cases:4.25%
controls:2.17%
cases:4.25%
controls:0.85%
—
—
—
—
—
—
—
—
cases:6.67%
controls:3.13%
9
46
203
2071
9
18
203
2099
—
—
—
—
13
60
182
1860
Eosinophils [#/volume] in Blood
26449-9 [3013115]
4.0e-01
6.2e-01
1.4e+00
—
—
9.3e-01
6.9e-01
cases:12.74%
controls:8.93%
cases:8.49%
controls:4.77%
cases:3.77%
controls:0.99%
—
—
—
—
cases:12.92%
controls:5.53%
cases:24.10%
controls:13.70%
27
189
185
1928
18
101
194
2016
8
21
204
2096
—
—
27
115
182
1964
47
263
148
1657
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
7.4e-01
1.6e+00
—
—
—
—
6.2e-01
cases:11.32%
controls:5.72%
cases:6.13%
controls:1.32%
—
—
—
—
—
—
—
—
cases:7.18%
controls:4.01%
24
121
188
1996
13
28
199
2089
—
—
—
—
14
77
181
1843
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
2.0e-01
3.1e-01
1.5e+00
—
2.0e-01
2.5e-01
2.4e-01
cases:22.64%
controls:19.27%
cases:19.81%
controls:15.30%
cases:13.68%
controls:3.26%
—
—
cases:3.77%
controls:3.12%
cases:19.62%
controls:16.02%
cases:38.97%
controls:33.33%
48
408
164
1709
42
324
170
1793
29
69
183
2048
—
8
66
204
2050
41
333
168
1746
76
640
119
1280
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
3.2e-01
6.1e-01
1.4e+00
—
—
8.8e-01
6.6e-01
cases:11.79%
controls:8.83%
cases:8.49%
controls:4.82%
cases:3.77%
controls:0.99%
—
—
—
—
cases:12.44%
controls:5.58%
cases:22.56%
controls:13.07%
25
187
187
1930
18
102
194
2015
8
21
204
2096
—
—
26
116
183
1963
44
251
151
1669
Normoblasts [#/volume] in Blood
715-3 [3021589]
-5.0e-02
6.2e-01
1.5e+00
—
—
2.3e-01
4.9e-01
cases:6.13%
controls:6.42%
cases:8.96%
controls:5.01%
cases:4.25%
controls:0.94%
—
—
—
—
cases:6.70%
controls:5.39%
cases:16.41%
controls:10.73%
13
136
199
1981
19
106
193
2011
9
20
203
2097
—
—
14
112
195
1967
32
206
163
1714
Orthopedic Surgery
20 [38004465]
7.6e-01
7.2e-01
—
—
—
5.5e-01
7.5e-01
cases:25.94%
controls:14.03%
cases:10.85%
controls:5.57%
—
—
—
—
—
—
cases:9.09%
controls:5.44%
cases:30.77%
controls:17.34%
55
297
157
1820
23
118
189
1999
—
—
—
19
113
190
1966
60
333
135
1587
Lumbar spine X-ray examination without contrast
NA3AA [2001307026]
1.5e+00
—
—
—
—
—
1.5e+00
cases:4.72%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
cases:4.10%
controls:0.94%
10
23
202
2094
—
—
—
—
—
8
18
187
1902
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
5.7e-01
—
—
—
—
—
1.5e+00
cases:3.30%
controls:1.89%
—
—
—
—
—
—
—
—
—
—
cases:6.15%
controls:1.51%
7
40
205
2077
—
—
—
—
—
12
29
183
1891
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
5.7e-01
8.7e-01
—
—
—
8.7e-02
3.4e-01
cases:26.42%
controls:16.91%
cases:11.32%
controls:5.05%
—
—
—
—
—
—
cases:5.74%
controls:5.29%
cases:20.00%
controls:15.16%
56
358
156
1759
24
107
188
2010
—
—
—
12
110
197
1969
39
291
156
1629
sulfadiazine and trimethoprim
J01EE02 [21602962]
1.4e+00
—
—
—
—
—
—
cases:4.72%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
10
25
202
2092
—
—
—
—
—
—
Osmolality of Urine
2695-5 [3026782]
7.2e-01
1.4e+00
—
—
—
—
8.3e-01
cases:6.13%
controls:3.07%
cases:5.19%
controls:1.32%
—
—
—
—
—
—
—
—
cases:7.69%
controls:3.49%
13
65
199
2052
11
28
201
2089
—
—
—
—
15
67
180
1853
Thorax X-ray examination
GD1AA [2001303617]
5.9e-01
8.2e-01
-1.0e+50
1.0e+50
—
1.4e+00
5.2e-01
cases:10.85%
controls:6.33%
cases:5.19%
controls:2.36%
cases:0.00%
controls:0.24%
cases:2.36%
controls:0.00%
—
—
cases:8.13%
controls:2.21%
cases:13.85%
controls:8.70%
23
134
189
1983
11
50
201
2067
0
5
212
2112
5
0
207
2117
—
17
46
192
2033
27
167
168
1753
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
4.6e-01
1.2e+00
—
—
—
1.3e+00
1.3e+00
cases:3.77%
controls:2.41%
cases:2.83%
controls:0.90%
—
—
—
—
—
—
cases:2.39%
controls:0.67%
cases:7.69%
controls:2.24%
8
51
204
2066
6
19
206
2098
—
—
—
5
14
204
2065
15
43
180
1877
Acute maxillary sinusitis
J01.0 [45601112]
1.3e+00
7.9e-01
—
—
—
1.1e+00
3.2e-01
cases:8.02%
controls:2.41%
cases:2.36%
controls:1.09%
—
—
—
—
—
—
cases:2.39%
controls:0.82%
cases:6.15%
controls:4.53%
17
51
195
2066
5
23
207
2094
—
—
—
5
17
204
2062
12
87
183
1833
Specific gravity of Urine by Refractometry
5810-7 [3019150]
6.3e-01
6.5e-01
—
—
—
1.2e+00
1.9e-01
cases:6.60%
controls:3.64%
cases:3.30%
controls:1.75%
—
—
—
—
—
—
cases:6.70%
controls:2.02%
cases:9.74%
controls:8.18%
14
77
198
2040
7
37
205
2080
—
—
—
14
42
195
2037
19
157
176
1763
Low back pain
M54.5 [45553207]
6.4e-01
1.2e+00
—
—
—
7.6e-01
6.3e-01
cases:8.96%
controls:4.91%
cases:5.66%
controls:1.70%
—
—
—
—
—
—
cases:4.31%
controls:2.07%
cases:11.79%
controls:6.67%
19
104
193
2013
12
36
200
2081
—
—
—
9
43
200
2036
23
128
172
1792
oxycodone and naloxone; oral
N02AA55 [21604265]
1.0e+00
—
—
—
—
—
1.2e+00
cases:4.25%
controls:1.56%
—
—
—
—
—
—
—
—
—
—
cases:7.69%
controls:2.45%
9
33
203
2084
—
—
—
—
—
15
47
180
1873
Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma
70200-1 [42868674]
3.5e-01
2.3e-01
—
—
—
3.1e-01
1.2e+00
cases:3.77%
controls:2.69%
cases:2.36%
controls:1.89%
—
—
—
—
—
—
cases:2.87%
controls:2.12%
cases:11.28%
controls:3.70%
8
57
204
2060
5
40
207
2077
—
—
—
6
44
203
2035
22
71
173
1849
Dyspnoea
R06.0 [45558449]
1.2e+00
1.3e+00
—
—
—
—
7.2e-01
cases:6.13%
controls:1.94%
cases:2.83%
controls:0.80%
—
—
—
—
—
—
—
—
cases:7.69%
controls:3.91%
13
41
199
2076
6
17
206
2100
—
—
—
—
15
75
180
1845
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
5.5e-01
1.2e+00
—
—
-1.0e+50
9.1e-01
5.4e-01
cases:6.60%
controls:3.92%
cases:6.13%
controls:1.94%
—
—
—
—
cases:0.00%
controls:0.43%
cases:4.78%
controls:1.97%
cases:10.77%
controls:6.56%
14
83
198
2034
13
41
199
2076
—
—
0
9
212
2107
10
41
199
2038
21
126
174
1794
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.6e-01
4.1e-01
1.2e+00
—
1.1e-02
2.8e-01
3.6e-01
cases:31.13%
controls:25.84%
cases:26.42%
controls:19.23%
cases:9.91%
controls:3.26%
—
—
cases:3.77%
controls:3.73%
cases:25.36%
controls:20.49%
cases:55.90%
controls:46.98%
66
547
146
1570
56
407
156
1710
21
69
191
2048
—
8
79
204
2037
53
426
156
1653
109
902
86
1018
tamsulosin; oral
G04CA02 [21602669]
1.2e+00
1.3e+00
—
—
—
7.4e-01
6.1e-01
cases:6.60%
controls:2.13%
cases:4.72%
controls:1.28%
—
—
—
—
—
—
cases:2.87%
controls:1.39%
cases:6.15%
controls:3.44%
14
45
198
2072
10
27
202
2090
—
—
—
6
29
203
2050
12
66
183
1854
Coloscopy
UJF32 [2001305029]
5.0e-01
—
—
—
—
—
1.2e+00
cases:4.72%
controls:2.93%
—
—
—
—
—
—
—
—
—
—
cases:8.21%
controls:2.71%
10
62
202
2055
—
—
—
—
—
16
52
179
1868
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]
6.9e-01
4.2e-01
—
—
—
—
1.2e+00
cases:6.13%
controls:3.16%
cases:2.36%
controls:1.56%
—
—
—
—
—
—
—
—
cases:6.67%
controls:2.19%
13
67
199
2050
5
33
207
2084
—
—
—
—
13
42
182
1878
chloramphenicol
S01AA01 [21603554]
6.7e-01
-1.2e-01
—
—
-1.0e+50
1.1e+00
4.1e-01
cases:13.21%
controls:7.23%
cases:2.36%
controls:2.65%
—
—
—
—
cases:0.00%
controls:0.24%
cases:7.18%
controls:2.41%
cases:14.87%
controls:10.36%
28
153
184
1964
5
56
207
2061
—
—
0
5
212
2111
15
50
194
2029
29
199
166
1721
chloramphenicol
S03AA08 [21605197]
6.7e-01
-1.2e-01
—
—
-1.0e+50
1.1e+00
4.1e-01
cases:13.21%
controls:7.23%
cases:2.36%
controls:2.65%
—
—
—
—
cases:0.00%
controls:0.24%
cases:7.18%
controls:2.41%
cases:14.87%
controls:10.36%
28
153
184
1964
5
56
207
2061
—
—
0
5
212
2111
15
50
194
2029
29
199
166
1721
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
3.0e-01
1.1e+00
-1.0e+50
—
—
7.9e-01
3.8e-01
cases:6.13%
controls:4.63%
cases:7.08%
controls:2.55%
cases:0.00%
controls:0.43%
—
—
—
—
cases:5.74%
controls:2.69%
cases:13.33%
controls:9.48%
13
98
199
2019
15
54
197
2063
0
9
212
2108
—
—
12
56
197
2023
26
182
169
1738
lansoprazole; oral
A02BC03 [21600098]
1.1e+00
4.5e-01
—
—
—
2.9e-01
4.9e-01
cases:13.68%
controls:5.20%
cases:4.25%
controls:2.74%
—
—
—
—
—
—
cases:3.83%
controls:2.89%
cases:7.69%
controls:4.84%
29
110
183
2007
9
58
203
2059
—
—
—
8
60
201
2019
15
93
180
1827
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
9.6e-01
9.3e-01
—
—
—
—
1.0e+00
cases:7.55%
controls:3.02%
cases:3.30%
controls:1.32%
—
—
—
—
—
—
—
—
cases:9.23%
controls:3.44%
16
64
196
2053
7
28
205
2089
—
—
—
—
18
66
177
1854
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
1.8e-01
8.8e-01
—
—
—
—
1.0e+00
cases:3.77%
controls:3.16%
cases:2.36%
controls:0.99%
—
—
—
—
—
—
—
—
cases:10.26%
controls:3.85%
8
67
204
2050
5
21
207
2096
—
—
—
—
20
74
175
1846
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
1.0e+00
1.3e+00
2.3e+00
—
—
8.5e-01
8.3e-01
cases:7.08%
controls:2.65%
cases:4.25%
controls:1.23%
cases:2.36%
controls:0.24%
—
—
—
—
cases:2.87%
controls:1.25%
cases:8.21%
controls:3.75%
15
56
197
2061
9
26
203
2091
5
5
207
2112
—
—
6
26
203
2053
16
72
179
1848
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1.0e+00
1.1e+00
—
—
-1.0e+50
2.2e-01
5.2e-01
cases:10.85%
controls:4.30%
cases:5.66%
controls:2.03%
—
—
—
—
cases:0.00%
controls:0.52%
cases:2.87%
controls:2.31%
cases:13.33%
controls:8.39%
23
91
189
2026
12
43
200
2074
—
—
0
11
212
2105
6
48
203
2031
26
161
169
1759
fluticasone, combinations
R01AD58 [43534837]
9.9e-01
5.5e-01
—
—
—
5.2e-01
1.4e-01
cases:8.96%
controls:3.54%
cases:2.83%
controls:1.65%
—
—
—
—
—
—
cases:2.87%
controls:1.73%
cases:6.67%
controls:5.83%
19
75
193
2042
6
35
206
2082
—
—
—
6
36
203
2043
13
112
182
1808
azelastine; nasal
R01AC03 [21605035]
9.9e-01
5.5e-01
—
—
—
5.2e-01
1.4e-01
cases:8.96%
controls:3.54%
cases:2.83%
controls:1.65%
—
—
—
—
—
—
cases:2.87%
controls:1.73%
cases:6.67%
controls:5.83%
19
75
193
2042
6
35
206
2082
—
—
—
6
36
203
2043
13
112
182
1808
Other primary gonarthrosis
M17.1 [45596493]
6.2e-01
—
—
—
—
—
9.7e-01
cases:4.72%
controls:2.60%
—
—
—
—
—
—
—
—
—
—
cases:9.23%
controls:3.70%
10
55
202
2062
—
—
—
—
—
18
71
177
1849
Other specified special examinations
Z01.8 [45581003]
8.6e-01
1.4e+00
—
—
—
1.5e+00
9.7e-01
cases:6.13%
controls:2.69%
cases:3.30%
controls:0.80%
—
—
—
—
—
—
cases:2.87%
controls:0.67%
cases:8.72%
controls:3.49%
13
57
199
2060
7
17
205
2100
—
—
—
6
14
203
2065
17
67
178
1853
Office Visit
OMOP4822458 [581477]
5.3e-01
2.3e-01
—
—
—
5.9e-01
9.5e-01
cases:13.68%
controls:8.50%
cases:2.83%
controls:2.27%
—
—
—
—
—
—
cases:3.83%
controls:2.16%
cases:14.36%
controls:6.09%
29
180
183
1937
6
48
206
2069
—
—
—
8
45
201
2034
28
117
167
1803
Basophils [#/volume] in Blood
26444-0 [3006315]
4.3e-01
6.7e-01
1.2e+00
—
—
9.4e-01
5.8e-01
cases:12.26%
controls:8.31%
cases:8.49%
controls:4.53%
cases:3.30%
controls:0.99%
—
—
—
—
cases:12.44%
controls:5.24%
cases:21.03%
controls:12.92%
26
176
186
1941
18
96
194
2021
7
21
205
2096
—
—
26
109
183
1970
41
248
154
1672
Monocytes [#/volume] in Blood
26484-6 [3001604]
4.4e-01
6.7e-01
1.2e+00
—
—
9.3e-01
6.0e-01
cases:12.26%
controls:8.27%
cases:8.49%
controls:4.53%
cases:3.30%
controls:0.99%
—
—
—
—
cases:12.44%
controls:5.29%
cases:21.03%
controls:12.71%
26
175
186
1942
18
96
194
2021
7
21
205
2096
—
—
26
110
183
1969
41
244
154
1676
Bacteria [Presence] in Urine
87829-8 [36304419]
5.5e-01
1.1e+00
2.1e+00
—
-1.0e+50
8.1e-01
9.0e-01
cases:6.13%
controls:3.64%
cases:4.72%
controls:1.70%
cases:2.36%
controls:0.28%
—
—
cases:0.00%
controls:0.43%
cases:3.83%
controls:1.73%
cases:11.28%
controls:4.90%
13
77
199
2040
10
36
202
2081
5
6
207
2111
—
0
9
212
2107
8
36
201
2043
22
94
173
1826
Gastroenterology
10 [38004455]
7.7e-01
8.3e-01
-1.0e+50
—
—
9.4e-01
8.5e-01
cases:8.49%
controls:4.11%
cases:4.25%
controls:1.89%
cases:0.00%
controls:0.24%
—
—
—
—
cases:4.78%
controls:1.92%
cases:11.79%
controls:5.42%
18
87
194
2030
9
40
203
2077
0
5
212
2112
—
—
10
40
199
2039
23
104
172
1816
Inpatient Hospital
21 [8717]
4.7e-01
8.2e-01
—
—
8.3e-01
5.3e-01
4.0e-01
cases:38.21%
controls:27.92%
cases:17.92%
controls:8.79%
—
—
—
—
cases:2.36%
controls:1.04%
cases:12.44%
controls:7.74%
cases:25.13%
controls:18.33%
81
591
131
1526
38
186
174
1931
—
—
5
22
207
2094
26
161
183
1918
49
352
146
1568
azithromycin; oral, parenteral
J01FA10 [21602978]
4.4e-01
7.6e-01
-1.0e+50
—
-1.0e+50
6.6e-02
8.1e-01
cases:14.15%
controls:9.59%
cases:4.72%
controls:2.27%
cases:0.00%
controls:0.43%
—
—
cases:0.00%
controls:0.28%
cases:2.87%
controls:2.69%
cases:12.82%
controls:6.15%
30
203
182
1914
10
48
202
2069
0
9
212
2108
—
0
6
212
2110
6
56
203
2023
25
118
170
1802
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
4.9e-01
8.0e-01
1.6e+00
—
—
6.1e-01
5.2e-01
cases:16.51%
controls:10.77%
cases:12.26%
controls:5.90%
cases:2.83%
controls:0.57%
—
—
—
—
cases:9.57%
controls:5.44%
cases:25.13%
controls:16.67%
35
228
177
1889
26
125
186
1992
6
12
206
2105
—
—
20
113
189
1966
49
320
146
1600
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
5.1e-01
8.5e-01
-1.0e+50
—
—
3.5e-01
7.9e-01
cases:12.74%
controls:8.08%
cases:6.60%
controls:2.93%
cases:0.00%
controls:0.61%
—
—
—
—
cases:4.31%
controls:3.08%
cases:13.85%
controls:6.82%
27
171
185
1946
14
62
198
2055
0
13
212
2104
—
—
9
64
200
2015
27
131
168
1789
Cardiology
6 [38004451]
5.6e-01
6.2e-01
—
—
—
5.0e-01
7.8e-01
cases:11.79%
controls:7.09%
cases:6.13%
controls:3.40%
—
—
—
—
—
—
cases:5.26%
controls:3.27%
cases:16.92%
controls:8.54%
25
150
187
1967
13
72
199
2045
—
—
—
11
68
198
2011
33
164
162
1756
metronidazole; oral, rectal
P01AB01 [21604857]
7.7e-01
6.8e-01
—
—
-1.0e+50
—
2.4e-01
cases:12.74%
controls:6.33%
cases:3.30%
controls:1.70%
—
—
—
—
cases:0.00%
controls:0.28%
—
—
cases:8.72%
controls:6.98%
27
134
185
1983
7
36
205
2081
—
—
0
6
212
2110
—
17
134
178
1786
esomeprazole; oral, parenteral
A02BC05 [21600100]
6.2e-01
1.7e-01
—
—
—
3.9e-01
7.2e-01
cases:15.09%
controls:8.69%
cases:5.19%
controls:4.39%
—
—
—
—
—
—
cases:7.18%
controls:4.95%
cases:16.41%
controls:8.70%
32
184
180
1933
11
93
201
2024
—
—
—
15
103
194
1976
32
167
163
1753
Monocytes/Leukocytes in Blood
26485-3 [3019069]
3.3e-01
5.6e-01
1.4e+00
—
—
7.5e-01
7.1e-01
cases:11.32%
controls:8.41%
cases:7.55%
controls:4.44%
cases:3.77%
controls:0.94%
—
—
—
—
cases:10.05%
controls:5.00%
cases:21.54%
controls:11.93%
24
178
188
1939
16
94
196
2023
8
20
204
2097
—
—
21
104
188
1975
42
229
153
1691
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
3.2e-01
5.6e-01
1.4e+00
—
—
7.5e-01
7.0e-01
cases:11.32%
controls:8.46%
cases:7.55%
controls:4.44%
cases:3.77%
controls:0.94%
—
—
—
—
cases:10.05%
controls:5.00%
cases:21.54%
controls:11.98%
24
179
188
1938
16
94
196
2023
8
20
204
2097
—
—
21
104
188
1975
42
230
153
1690
Basophils/Leukocytes in Blood
30180-4 [3022096]
3.2e-01
5.6e-01
1.4e+00
—
—
7.6e-01
6.9e-01
cases:11.32%
controls:8.46%
cases:7.55%
controls:4.44%
cases:3.77%
controls:0.94%
—
—
—
—
cases:10.05%
controls:4.95%
cases:21.54%
controls:12.08%
24
179
188
1938
16
94
196
2023
8
20
204
2097
—
—
21
103
188
1976
42
232
153
1688
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
3.8e-01
6.4e-01
3.0e-01
—
4.7e-01
1.1e-01
-2.2e-02
cases:47.17%
controls:37.84%
cases:27.83%
controls:16.86%
cases:3.30%
controls:2.46%
—
—
cases:3.30%
controls:2.08%
cases:20.10%
controls:18.33%
cases:41.54%
controls:42.08%
100
801
112
1316
59
357
153
1760
7
52
205
2065
—
7
44
205
2072
42
381
167
1698
81
808
114
1112
ibuprofen
R02AX02 [1588667]
3.8e-01
6.4e-01
3.0e-01
—
4.7e-01
1.1e-01
-2.2e-02
cases:47.17%
controls:37.84%
cases:27.83%
controls:16.86%
cases:3.30%
controls:2.46%
—
—
cases:3.30%
controls:2.08%
cases:20.10%
controls:18.33%
cases:41.54%
controls:42.08%
100
801
112
1316
59
357
153
1760
7
52
205
2065
—
7
44
205
2072
42
381
167
1698
81
808
114
1112
Ophthalmology
18 [38004463]
3.4e-01
3.2e-01
9.3e-01
—
—
5.3e-01
6.2e-01
cases:16.51%
controls:12.38%
cases:7.55%
controls:5.62%
cases:2.36%
controls:0.94%
—
—
—
—
cases:10.05%
controls:6.16%
cases:25.13%
controls:15.26%
35
262
177
1855
16
119
196
1998
5
20
207
2097
—
—
21
128
188
1951
49
293
146
1627
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
4.8e-01
6.2e-01
2.5e-01
—
1.3e-01
2.0e-01
3.6e-01
cases:41.51%
controls:30.51%
cases:25.94%
controls:15.82%
cases:2.83%
controls:2.22%
—
—
cases:2.83%
controls:2.50%
cases:19.62%
controls:16.64%
cases:50.26%
controls:41.25%
88
646
124
1471
55
335
157
1782
6
47
206
2070
—
6
53
206
2063
41
346
168
1733
98
792
97
1128
Laparoscopic cholecystectomy
JKA21 [2001305294]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
—
—
0
19
212
2098
—
—
—
—
—
—
Guidance concerning treatment of rash and skin
SPAT1156 [2001700257]
5.5e-01
—
—
—
—
—
7.6e-01
cases:2.36%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
cases:3.59%
controls:1.72%
5
29
207
2088
—
—
—
—
—
7
33
188
1887
insulin lispro; parenteral
A10AD04 [21600732]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
8
212
2109
—
0
8
212
2108
—
—
SCL-70 extractable nuclear Ab [Presence] in Serum by Immunoblot
56693-5 [40759812]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
212
2112
—
—
—
—
—
—
Diarrhoea
D11 [2002000310]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
26
212
2091
—
—
—
—
—
—
Other specified counselling
Z71.8 [45581061]
2.0e-01
—
—
—
—
4.6e-01
2.3e-01
cases:3.77%
controls:3.12%
—
—
—
—
—
—
—
—
cases:2.87%
controls:1.83%
cases:8.72%
controls:7.08%
8
66
204
2051
—
—
—
—
6
38
203
2041
17
136
178
1784
losartan and diuretics
C09DA01 [21601834]
—
—
—
—
—
—
-1.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.56%
controls:3.07%
—
—
—
—
—
—
5
59
190
1861
hydrocortisone and antiinfectives
S01CA03 [21603654]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
0
9
212
2108
—
—
—
—
—
Other specified anxiety disorders
F41.8 [45595908]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
212
2107
—
—
—
—
—
—
Ventricular premature depolarization
I49.3 [45538386]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.76%
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
0
16
212
2101
0
8
212
2109
—
—
—
—
—
Clinical photography of mouth and teeth
SBB00 [2001310298]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
212
2110
—
—
—
—
—
—
Testosterone Free [Moles/volume] in Serum or Plasma by calculation
96559-0 [36032269]
2.3e+00
—
—
—
—
—
—
cases:2.36%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
5
5
207
2112
—
—
—
—
—
—
Cardiodefibrillation
TFP20 [2001303224]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
0
14
195
1906
Skin Pathology biopsy report
65754-4 [40768443]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
0
6
209
2073
—
tretinoin; ointment
D10AD01 [21602293]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
0
5
212
2112
—
—
—
—
0
8
195
1912
TREATMENT - Kidney transplant
TREATMENT-51 [2002330239]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
212
2112
—
—
—
—
—
—
Procalcitonin [Mass/volume] in Serum or Plasma
33959-8 [3046279]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
13
195
1907
Custom moulded splint, unspecified region
TNX32 [2001308563]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
0
5
212
2112
—
—
—
—
—
Presenil cataract
H26.02 [2000502303]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
212
2110
—
—
—
—
—
—
pH of Venous blood
2746-6 [3012544]
—
—
—
—
—
—
8.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.62%
controls:2.08%
—
—
—
—
—
—
9
40
186
1880
hepatitis B, purified antigen
J07BC01 [21601338]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
212
2103
—
—
—
—
—
—
saccharomyces boulardii; oral
A07FA02 [21600670]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
0
10
209
2069
—
Missed abortion
O02.1 [45567878]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
212
2111
—
—
—
—
—
—
Sprain and strain of elbow
S53.4 [45549825]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
195
1915
levofloxacin
S01AE05 [43534860]
-1.0e+50
—
—
—
—
—
7.5e-01
cases:0.00%
controls:1.42%
—
—
—
—
—
—
—
—
—
—
cases:4.10%
controls:1.98%
0
30
212
2087
—
—
—
—
—
8
38
187
1882
pH of Urine by Test strip
5803-2 [3022621]
1.3e+00
—
—
—
—
—
4.5e-01
cases:2.83%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
cases:3.08%
controls:1.98%
6
17
206
2100
—
—
—
—
—
6
38
189
1882
Esophagoscopy, gastroscopy and duodenoscopy
SPAT1130 [2001700231]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
195
1915
Astigmatism
H52.2 [45547934]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
0
10
212
2107
—
—
—
—
—
0
5
195
1915
Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection
13956-8 [3014162]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
cases:0.00%
controls:0.68%
—
—
—
—
—
0
5
209
2074
0
13
195
1907
Medical observation and evaluation for suspected diseases and conditions, ruled out
Z03 [45552058]
—
—
—
—
—
-1.0e+50
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
cases:2.56%
controls:0.89%
—
—
—
—
—
0
5
209
2074
5
17
190
1903
thiamine (vit B1); oral, parenteral
A11DA01 [21600825]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
212
2109
—
—
—
—
—
—
Chronic glaucoma with open ventricular angle
H40.13 [2000502335]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
0
8
212
2109
—
—
—
0
7
209
2072
—
Glucose [Moles/volume] in Venous blood
39480-9 [3038515]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
212
2112
—
—
—
—
—
—
FEV1/FVC
19926-5 [3011505]
8.3e-01
—
—
—
—
—
1.5e+00
cases:3.30%
controls:1.46%
—
—
—
—
—
—
—
—
—
—
cases:3.59%
controls:0.83%
7
31
205
2086
—
—
—
—
—
7
16
188
1904
Radical radiotherapy
WF002 [2001310701]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
0
11
212
2106
—
—
—
—
—
0
7
195
1913
Follitropin [Units/volume] in Serum or Plasma by Immunoassay
83098-4 [42529215]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
0
6
212
2111
—
—
—
—
—
0
8
195
1912
Other administrative function
SPAT1281 [2001700382]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
212
2105
—
—
—
—
—
—
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
1.7e-01
—
-1.0e+50
—
—
7.0e-01
8.0e-01
cases:3.77%
controls:3.21%
—
—
cases:0.00%
controls:0.24%
—
—
—
—
cases:2.39%
controls:1.20%
cases:9.23%
controls:4.38%
8
68
204
2049
—
0
5
212
2112
—
—
5
25
204
2054
18
84
177
1836
Neurosurgery
14 [38004459]
—
—
—
—
—
—
6.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.62%
controls:2.45%
—
—
—
—
—
—
9
47
186
1873
Type 1 diabetes mellitus, With other specified complications
E10.6 [45537959]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
212
2112
—
—
—
—
—
—
Striking against or struck by other object(s)
W22 [45756260]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
0
5
209
2074
—
Functional endoscopic opening of maxillary antrum
DMB20 [2001301780]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
0
14
212
2103
—
—
—
—
—
0
7
195
1913
Benign and innocent cardiac murmurs
R01.0 [45563286]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
195
1915
The fear of childbirth
O99.80 [2000503219]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
212
2112
—
—
—
—
—
—
Fracture of other specified cervical vertebra
S12.2 [45568286]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
212
2112
—
—
—
—
—
—
Incomplete uterovaginal prolapse
N81.2 [45596883]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
7
195
1913
Cathetrisation of vein
TPH04 [2001309597]
1.5e-01
—
—
—
—
—
2.6e-01
cases:2.83%
controls:2.46%
—
—
—
—
—
—
—
—
—
—
cases:4.62%
controls:3.59%
6
52
206
2065
—
—
—
—
—
9
69
186
1851
Type 1 diabetes mellitus, With multiple complications
E10.7 [45571655]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.85%
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
0
18
212
2099
0
11
212
2106
—
—
—
—
0
23
195
1897
covid-19, RNA-based vaccine
J07BN01 [954934]
-3.7e-02
2.0e-01
—
—
—
1.3e-01
-5.0e-02
cases:7.08%
controls:7.32%
cases:8.49%
controls:7.09%
—
—
—
—
—
—
cases:10.53%
controls:9.33%
cases:21.03%
controls:21.88%
15
155
197
1962
18
150
194
1967
—
—
—
22
194
187
1885
41
420
154
1500
Persons encountering health services in other specified circumstances
Z76.8 [45542457]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
0
8
212
2109
—
—
—
—
—
0
8
195
1912
Glucose [Moles/volume] in Urine
15076-3 [3005570]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
7
195
1913
biperiden; oral, parenteral
N04AA02 [21604447]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
195
1915
Choriogonadotropin.beta subunit free [Mass/volume] in Serum or Plasma
25373-2 [3019145]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.52%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
0
11
212
2106
0
6
212
2111
—
—
—
—
—
capecitabine
L01BC06 [21601440]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
212
2112
—
—
—
—
—
—
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
0
13
212
2104
—
—
—
—
—
Colonoscopy Study observation
28023-0 [3022145]
1.2e+00
—
—
—
—
—
4.0e-01
cases:3.77%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
cases:3.08%
controls:2.08%
8
25
204
2092
—
—
—
—
—
6
40
189
1880
Melanocytic naevi, unspecified
D22.9 [45571603]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
212
2112
—
—
—
—
—
—
Morphology ultrasound screening, weeks 18+0 to 21+6 of gestation
MA5AE [2001306841]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
212
2110
—
—
—
—
—
—
Colonoscopy
SPAT1131 [2001700232]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
195
1915
Unspecified lump in breast
N63 [45601743]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
10
195
1910
Embedded teeth
K01.0 [45548133]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
195
1915
pravastatin; oral
C10AA03 [21601858]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
cases:0.00%
controls:0.53%
cases:0.00%
controls:0.57%
—
0
10
212
2107
—
—
—
0
11
209
2068
0
11
195
1909
Telephone, letter or other consultation without direct patient contact
ZY020 [2001311600]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
212
2103
—
—
—
—
—
—
Helicobacter pylori Ab [Presence] in Serum
22310-7 [3038177]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
212
2112
—
—
—
—
—
—
Submucous leiomyoma of uterus
D25.0 [45542691]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
212
2111
—
—
—
—
—
—
alfacalcidol; oral, parenteral
A11CC03 [21600818]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
cases:0.00%
controls:0.24%
cases:0.00%
controls:0.36%
0
13
212
2104
0
6
212
2111
—
—
—
0
5
209
2074
0
7
195
1913
piroxicam; ointment
M02AA07 [21604043]
8.5e-01
—
—
—
—
—
-9.5e-02
cases:6.60%
controls:2.93%
—
—
—
—
—
—
—
—
—
—
cases:2.56%
controls:2.81%
14
62
198
2055
—
—
—
—
—
5
54
190
1866
fluorometholone
S01BA07 [21603624]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
0
5
212
2112
—
—
—
0
6
209
2073
—
Calcitriol [Moles/volume] in Serum or Plasma
14566-4 [3011391]
—
—
1.0e+50
—
—
—
—
—
—
—
—
cases:2.83%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
6
0
206
2117
—
—
—
—
Laparoscopic repair of inguinal hernia
JAB11 [2001304390]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
212
2112
—
—
—
—
—
—
tamoxifen; oral
L02BA01 [21603831]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.66%
cases:0.00%
controls:0.38%
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
0
14
212
2103
0
8
212
2109
—
—
—
0
9
209
2070
—
Thyroperoxidase Ab [Units/volume] in Serum or Plasma
8099-4 [3027238]
—
—
—
—
—
—
6.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.08%
controls:1.61%
—
—
—
—
—
—
6
31
189
1889
hydrocortisone
S02BA01 [21605166]
6.3e-01
1.8e-01
—
—
—
1.5e-01
2.7e-01
cases:8.96%
controls:4.96%
cases:2.36%
controls:1.98%
—
—
—
—
—
—
cases:2.39%
controls:2.07%
cases:7.69%
controls:5.99%
19
105
193
2012
5
42
207
2075
—
—
—
5
43
204
2036
15
115
180
1805
calcium carbonate
A02AC01 [21600065]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
0
5
212
2112
—
—
—
0
5
209
2074
—
Migraine without aura [common migraine]
G43.0 [45600784]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
0
5
209
2074
—
Surface analgesia on skin or mucosa
WX105 [2001310765]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.10%
controls:1.15%
—
—
—
—
—
—
8
22
187
1898
Dislocation of shoulder joint
S43.0 [45573622]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
0
5
209
2074
—
Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection
92695-6 [37019628]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
0
16
195
1904
Primary arthrosis of other joints
M19.0 [45601353]
—
—
—
—
—
-1.0e+50
4.5e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
cases:3.08%
controls:1.98%
—
—
—
—
—
0
13
209
2066
6
38
189
1882
Ultrasound examination of lower leg veins
PH2AE [2001309451]
5.9e-01
-1.0e+50
—
—
—
—
—
cases:2.36%
controls:1.32%
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
5
28
207
2089
0
11
212
2106
—
—
—
—
—
zopiclone; oral
N05CF01 [21604654]
1.4e-01
4.0e-01
—
—
—
2.3e-01
4.3e-01
cases:8.49%
controls:7.46%
cases:5.66%
controls:3.87%
—
—
—
—
—
—
cases:4.78%
controls:3.85%
cases:9.74%
controls:6.56%
18
158
194
1959
12
82
200
2035
—
—
—
10
80
199
1999
19
126
176
1794
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.62%
controls:1.61%
—
—
—
—
—
—
9
31
186
1889
Epistaxis
R04.0 [45606791]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
20
195
1900
Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep
18500-9 [3018006]
4.6e-01
—
—
—
—
—
5.4e-01
cases:3.77%
controls:2.41%
—
—
—
—
—
—
—
—
—
—
cases:6.15%
controls:3.70%
8
51
204
2066
—
—
—
—
—
12
71
183
1849
Planned health check-up monitoring, health check-up performed based on individual need
SPAT1317 [2001700418]
—
—
—
—
—
—
9.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.56%
controls:1.04%
—
—
—
—
—
—
5
20
190
1900
Benign neoplasm: Sigmoid colon
D12.5 [45552326]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
212
2111
—
—
—
—
—
—
Iron deficiency anaemia
D50 [45571628]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
195
1914
Adjustment and management of cardiac devices
Z45.0 [45595515]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
8
195
1912
methotrexate; oral, parenteral
L04AX03 [21603929]
5.2e-01
—
-1.0e+50
—
—
—
9.2e-02
cases:2.36%
controls:1.42%
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
cases:2.56%
controls:2.34%
5
30
207
2087
—
0
13
212
2104
—
—
—
5
45
190
1875
insulin (beef); parenteral
A10AD02 [21600730]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
0
19
212
2098
—
0
18
212
2098
—
—
Type 2 diabetes mellitus, with peripheral circulatory complications
E11.5 [45557114]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
0
9
212
2108
—
—
—
—
—
0
5
195
1915
Psychiatry
26 [38004469]
-1.5e-01
-2.5e-01
—
—
—
2.7e-01
5.3e-01
cases:5.19%
controls:6.00%
cases:2.83%
controls:3.59%
—
—
—
—
—
—
cases:4.31%
controls:3.32%
cases:8.72%
controls:5.31%
11
127
201
1990
6
76
206
2041
—
—
—
9
69
200
2010
17
102
178
1818
Thyrotropin receptor Ab [Units/volume] in Serum
5385-0 [3017044]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.56%
controls:0.31%
—
—
—
—
—
—
5
6
190
1914
hyaluronic acid
S01KA01 [21605114]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
195
1915
Atherosclerotic heart disease
I25.1 [45596196]
8.4e-02
—
—
—
—
—
-2.4e-01
cases:2.36%
controls:2.17%
—
—
—
—
—
—
—
—
—
—
cases:2.56%
controls:3.23%
5
46
207
2071
—
—
—
—
—
5
62
190
1858
Extraction of root of tooth
EBA30 [2001301929]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
0
6
209
2073
—
Contact with and exposure to other communicable diseases
Z20.8 [45542410]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
12
212
2105
—
—
—
—
—
Hemoglobin [Entitic mass] in Reticulocytes
42810-2 [3029080]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
195
1915
Insulin-dependent diabetes mellitus - Diabetic retinopathy
H36.09*E10.3 [2000502327]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
195
1915
Sytologyspecimen from mouth of uterus
XLD00 [2001306651]
—
—
—
—
—
-1.0e+50
1.0e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
cases:2.56%
controls:0.94%
—
—
—
—
—
0
7
209
2072
5
18
190
1902
Rehabilitation Hospital
283X00000X [38004285]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.57%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
0
12
212
2105
0
5
212
2112
—
—
—
—
0
10
195
1910
Ultrsound examination of soft tissue not elsewhere classified
QX2XE [2001310033]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
10
195
1910
Human epididymis protein 4 [Moles/volume] in Serum or Plasma
55180-4 [40758310]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
212
2109
—
—
—
—
—
—
Infiltrating duct carcinoma, NOS, of breast, NOS
8500/3-C50.9 [44505315]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
0
7
212
2110
—
—
—
—
—
0
5
195
1915
Sequelae of cerebral infarction
I69.3 [45533476]
-1.0e+50
-1.0e+50
—
—
—
—
9.2e-01
cases:0.00%
controls:0.80%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
cases:2.56%
controls:1.04%
0
17
212
2100
0
6
212
2111
—
—
—
—
5
20
190
1900
hydrocortisone and antiseptics
D07BA04 [21602146]
7.4e-01
—
—
—
—
—
—
cases:2.83%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
—
6
29
206
2088
—
—
—
—
—
—
Insertion or removal of intrauterine contraceptive device
SPAT1190 [2001700291]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
0
7
212
2110
—
—
—
—
—
0
9
195
1911
Shoulder lesion, unspecified
M75.9 [45557986]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
cases:0.00%
controls:0.63%
0
6
212
2111
—
—
—
—
0
7
209
2072
0
12
195
1908
Cellulitis of finger and toe
L03.0 [45557691]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
0
10
209
2069
—
Functional dyspepsia
K30 [45591584]
1.2e+00
—
—
—
—
-1.0e+50
4.8e-01
cases:2.36%
controls:0.71%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
cases:3.08%
controls:1.93%
5
15
207
2102
—
—
—
—
0
8
209
2071
6
37
189
1883
Malignant neoplasm prostate
Y77 [2002001445]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
0
5
209
2074
—
Exposure to unspecified factor
X59 [45756412]
6.4e-01
—
—
—
—
—
-5.6e-02
cases:3.77%
controls:2.03%
—
—
—
—
—
—
—
—
—
—
cases:2.56%
controls:2.71%
8
43
204
2074
—
—
—
—
—
5
52
190
1868
Chronic hypertension
205 [2001600203]
4.4e-01
-1.0e+50
—
—
—
—
—
cases:2.83%
controls:1.84%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
6
39
206
2078
0
6
212
2111
—
—
—
—
—
Shoulder syndrome
L92 [2002000711]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
7
195
1913
Bacteria identified in Blood by Culture
600-7 [3023368]
4.5e-01
—
—
—
-1.0e+50
—
5.0e-01
cases:4.25%
controls:2.74%
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
cases:7.18%
controls:4.48%
9
58
203
2059
—
—
—
0
5
212
2111
—
14
86
181
1834
Contusion of knee
S80.0 [45569633]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
0
9
209
2070
—
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
6.1e-01
7.6e-01
-1.0e+50
—
—
—
5.7e-01
cases:11.79%
controls:6.75%
cases:4.72%
controls:2.27%
cases:0.00%
controls:0.66%
—
—
—
—
—
—
cases:11.79%
controls:7.03%
25
143
187
1974
10
48
202
2069
0
14
212
2103
—
—
—
23
135
172
1785
Glucose tolerance 2 hours panel - Serum or Plasma
72171-2 [43054914]
—
—
—
—
—
—
2.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.08%
controls:2.34%
—
—
—
—
—
—
6
45
189
1875
Phakoemulsification with implantation of artificial lens in posterior chamber
CJE20 [2001301342]
—
—
—
—
—
—
1.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.59%
controls:3.02%
—
—
—
—
—
—
7
58
188
1862
Major dressing of wound of skin of trunk
QBB10 [2001309842]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
195
1914
Gingivitis (chronic) NOS
K05.10 [2000502717]
—
—
—
—
—
-1.0e+50
7.6e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
cases:5.64%
controls:2.71%
—
—
—
—
—
0
10
209
2069
11
52
184
1868
Gingivitis (chronic) ulcerative
K05.19 [2000502722]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
212
2111
—
—
—
—
—
—
sucralfate; oral
A02BX02 [21600111]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
212
2112
—
—
—
—
—
—
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
6.6e-01
—
—
—
—
—
—
cases:2.36%
controls:1.23%
—
—
—
—
—
—
—
—
—
—
—
—
5
26
207
2091
—
—
—
—
—
—
Glaucoma, unspecified
H40.9 [45547899]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
212
2112
—
—
—
—
—
—
Plastic repair of septum of nose
DJD20 [2001301709]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
212
2110
—
—
—
—
—
—
mianserin; oral
N06AX03 [21604732]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
212
2107
—
—
—
—
—
—
Varicella zoster virus Ab [Titer] in Serum
21594-7 [3014148]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
212
2112
—
—
—
—
—
—
Repeated or continuing anesthesia shots throug a catheter
WX602 [2001310813]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
0
5
212
2112
—
—
—
—
—
Very demanding periodontal treatment
SDA05 [2001310330]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
0
6
212
2111
—
—
—
—
—
Injection of diagnostic or therapeutic substance in ankle joint or foot joint
TNH11 [2001308401]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
195
1915
fluticasone furoate; nasal
R01AD12 [21605053]
-1.2e-01
—
—
—
—
6.3e-01
2.0e-01
cases:8.96%
controls:10.01%
—
—
—
—
—
—
—
—
cases:7.66%
controls:4.23%
cases:10.77%
controls:9.01%
19
212
193
1905
—
—
—
—
16
88
193
1991
21
173
174
1747
cyanocobalamin; nasal, oral, parenteral
B03BA01 [21601121]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
0
5
209
2074
—
phenoxymethylpenicillin; oral
J01CE02 [21602842]
6.6e-02
5.1e-01
—
—
-1.0e+50
-2.5e-01
2.6e-02
cases:16.04%
controls:15.16%
cases:6.13%
controls:3.78%
—
—
—
—
cases:0.00%
controls:0.47%
cases:2.87%
controls:3.66%
cases:13.85%
controls:13.54%
34
321
178
1796
13
80
199
2037
—
—
0
10
212
2106
6
76
203
2003
27
260
168
1660
Cervical spine MRI examination with high intensity magnet
NA1BG [2001306990]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
10
195
1910
Sterilization
Z30.2 [45609921]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
195
1914
Examination of eyes and vision
Z01.0 [45566391]
8.6e-01
—
—
—
—
—
2.7e-01
cases:4.25%
controls:1.84%
—
—
—
—
—
—
—
—
—
—
cases:3.59%
controls:2.76%
9
39
203
2078
—
—
—
—
—
7
53
188
1867
Fracture of lower end of radius
S52.5 [45573842]
1.2e+00
—
—
—
—
—
—
cases:2.36%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
5
16
207
2101
—
—
—
—
—
—
Left side
ZXA05 [2001311347]
6.0e-01
—
—
—
—
—
9.3e-02
cases:6.13%
controls:3.45%
—
—
—
—
—
—
—
—
—
—
cases:3.59%
controls:3.28%
13
73
199
2044
—
—
—
—
—
7
63
188
1857
dydrogesterone; oral
G03DB01 [21602544]
3.9e-01
—
—
—
—
—
—
cases:2.36%
controls:1.61%
—
—
—
—
—
—
—
—
—
—
—
—
5
34
207
2083
—
—
—
—
—
—
propranolol; oral, parenteral
C07AA05 [21601670]
4.8e-01
1.7e-01
—
—
—
3.2e-01
-2.7e-02
cases:7.08%
controls:4.49%
cases:2.83%
controls:2.41%
—
—
—
—
—
—
cases:3.35%
controls:2.45%
cases:5.13%
controls:5.26%
15
95
197
2022
6
51
206
2066
—
—
—
7
51
202
2028
10
101
185
1819
Diabetes non-insulin dependent
T90 [2002001131]
9.7e-02
2.8e-01
—
—
—
4.8e-01
-1.7e-02
cases:4.72%
controls:4.30%
cases:3.77%
controls:2.88%
—
—
—
—
—
—
cases:5.26%
controls:3.32%
cases:7.69%
controls:7.81%
10
91
202
2026
8
61
204
2056
—
—
—
11
69
198
2010
15
150
180
1770
Parainfluenza type 3 nucleic acid detection
222361000000104 [44790049]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
8
195
1912
Influenza virus A Ag [Presence] in Specimen
31859-2 [3002523]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
195
1914
Cladosporium herbarum IgE Ab [Units/volume] in Serum
6075-6 [3005136]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
212
2110
—
—
—
—
—
—
betamethasone
S03BA03 [21605203]
9.2e-01
—
—
—
—
—
1.1e+00
cases:4.72%
controls:1.94%
—
—
—
—
—
—
—
—
—
—
cases:5.13%
controls:1.82%
10
41
202
2076
—
—
—
—
—
10
35
185
1885
Radiological examination, not elsewhere classified
Z01.6 [45605096]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.32%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
0
28
212
2089
—
—
—
—
0
6
209
2073
—
Thyrotoxicosis with diffuse goitre
E05.0 [45600628]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
0
10
212
2107
—
—
—
—
—
0
5
195
1915
Sampling
SPAT1263 [2001700364]
4.6e-01
4.6e-01
—
—
—
3.2e-01
5.1e-01
cases:9.91%
controls:6.47%
cases:4.72%
controls:3.02%
—
—
—
—
—
—
cases:4.31%
controls:3.17%
cases:12.31%
controls:7.76%
21
137
191
1980
10
64
202
2053
—
—
—
9
66
200
2013
24
149
171
1771
acetylcysteine
V03AB23 [21605248]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
195
1914
Sepsis, unspecified
A41.9 [45585911]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
195
1914
Skin symptom/complaint other
S29 [2002000993]
—
-1.0e+50
—
—
—
—
-5.0e-02
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
cases:3.08%
controls:3.23%
—
0
15
212
2102
—
—
—
—
6
62
189
1858
budesonide; inhalant
R03BA02 [21603285]
-1.3e-01
-1.7e-01
—
—
—
2.2e-01
4.5e-01
cases:4.72%
controls:5.34%
cases:2.36%
controls:2.79%
—
—
—
—
—
—
cases:3.35%
controls:2.69%
cases:7.69%
controls:5.05%
10
113
202
2004
5
59
207
2058
—
—
—
7
56
202
2023
15
97
180
1823

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
120
139
18.48
106.45
3.9
3.9
60.70
76.23
ng/l
1.60
108
126
116
242
9.33
60.93
3.0
7.0
0.90
1.03
mmol/l
5.65
108
228
170
845
6.01
28.39
5.1
2.5
78.04
77.01
nmol/l
0.22
159
764
179
941
6.65
27.57
11.1
8.1
1.23
1.21
mmol/l
2.45
157
817
165
850
5.18
24.95
9.0
7.3
1.23
1.21
mmol/l
1.54
155
787
28
39
8.11
19.57
2.9
2.4
5.74
6.83
pmol/l
0.36
28
39
29
17
19.53
19.34
1.3
1.2
127.28
113.41
pmol/l
0.61
29
17
15
0
+∞
15.82
1.4
0.0
301.80
—
umol/24h
—
15
0
53
166
3.92
15.07
8.5
4.7
7.36
7.33
ph
0.44
41
115
21
11
20.99
14.56
2.1
1.2
161.00
185.33
mmol/24h
0.36
21
11
105
523
2.99
13.84
2.3
3.1
328.14
335.63
umol/l
0.39
95
460
112
581
2.96
13.65
5.8
4.6
7.40
7.40
ph
1.16
95
406
11
0
+∞
11.56
1.5
0.0
2.31
—
mmol/24h
—
11
0
11
0
+∞
11.56
1.2
0.0
27.83
—
mg/24h
—
11
0
114
658
2.58
10.45
3.6
3.3
2.35
2.35
mmol/l
0.12
101
596
72
338
2.71
10.02
2.2
3.7
0.83
0.82
mmol/l
0.49
66
323
26
67
4.28
9.45
1.8
4.3
154.33
299.06
mg/l
—
6
31
14
9
16.53
9.16
1.8
1.3
66.83
56.24
ng/l
—
14
9
35
121
3.26
8.33
1.7
3.2
—
—
—
0
0
188
1477
3.32
7.99
7.6
9.0
75.74
78.69
u/l
0.62
182
1403
37
143
2.92
7.26
1.7
3.7
68.31
66.88
g/l
0.81
32
134
75
421
2.21
6.64
3.2
2.7
3.05
4.40
e6/l
1.36
68
378
97
620
2.04
5.98
2.4
2.6
57.70
61.94
u/l
0.24
87
573
38
169
2.52
5.65
1.1
1.2
—
—
—
0
0
12
17
7.41
5.52
3.3
3.1
—
—
—
0
0
105
707
1.96
5.44
4.8
3.7
21.66
121.30
e6/l
1.15
78
483
95
620
1.96
5.38
4.1
3.1
84.13
37.48
e6/l
0.55
75
467
44
215
2.32
5.32
2.5
2.1
348.45
384.57
nmol/l
0.58
44
203
5
0
+∞
5.23
1.0
0.0
538.80
—
mg/24h
—
5
0
20
65
3.29
5.22
2.8
2.6
25.11
24.83
mmol/l
0.13
20
65
78
487
1.95
4.95
1.4
1.3
1.04
1.47
u/ml
0.35
23
134
30
127
2.59
4.92
3.9
3.7
7.43
7.42
ph
1.09
24
104
116
828
1.88
4.86
4.1
5.1
37.05
36.15
g/l
1.14
110
792
178
1481
2.23
4.61
5.6
4.4
14.89
14.65
pmol/l
0.65
167
1363
168
1374
2.05
4.46
3.1
3.6
43.61
49.24
u/l
0.57
157
1304
17
56
3.21
4.35
2.6
4.8
111.42
1.64
ratio
0.49
12
34
33
158
2.29
4.15
2.5
2.5
0.21
0.16
e6/l
0.27
33
151
59
353
1.93
4.15
4.0
2.8
582.12
541.93
mosm/kgh2o
0.94
51
305
98
690
1.78
4.08
3.4
3.5
8.16
7.99
mmol/l
0.14
82
593
10
19
5.47
3.87
1.5
1.1
—
—
—
0
0
102
735
1.74
3.86
2.3
2.1
—
—
—
0
0
198
1760
2.77
3.81
7.0
5.4
1.82
1.89
mu/l
0.40
185
1636
48
280
1.92
3.60
1.4
1.3
—
—
—
0
0
13
36
3.78
3.56
4.5
2.4
93.10
89.35
%
1.33
13
36
62
396
1.80
3.50
1.5
1.3
18.10
27.09
iu/ml
0.49
17
122
74
498
1.74
3.49
4.9
2.9
—
—
—
0
0
204
1881
3.00
3.47
15.7
15.2
20.59
22.86
mg/l
0.41
165
1517
11
27
4.24
3.45
1.8
1.3
39.05
34.28
ng/l
0.09
11
27
78
535
1.72
3.43
4.2
3.0
0.17
0.47
e6/l
1.37
59
382
50
303
1.85
3.33
1.5
1.3
424.00
482.46
titre
—
10
65
68
453
1.74
3.30
1.5
1.4
2.00
2.39
g/l
1.42
38
281
7
11
6.54
3.21
1.9
3.3
358.14
826.82
u/ml
—
7
11
201
1830
2.75
3.10
6.1
5.1
5.86
5.91
mmol/l
0.30
188
1704
139
1129
1.67
3.09
5.1
5.3
6.63
6.64
mmol/l
0.02
131
1073
8
16
5.15
3.08
4.3
5.1
—
—
—
0
0
15
57
2.76
3.03
1.9
2.1
—
—
—
0
0
96
715
1.62
3.00
4.3
3.4
15.29
118.05
ng/l
0.66
72
482
5
6
8.49
2.76
1.0
1.0
104.80
51.00
nmol/24h
—
5
6
55
363
1.69
2.71
1.5
1.3
13.46
7.42
u/ml
0.25
20
143
104
804
1.57
2.70
4.3
3.5
6.16
6.18
ph
0.09
64
462
119
949
1.58
2.70
4.9
6.9
28.95
28.03
%
0.35
112
913
88
655
1.59
2.69
4.8
6.6
—
—
—
0
0
19
87
2.30
2.66
1.4
1.2
—
1.94
—
0
5
124
1001
1.57
2.65
5.3
3.8
0.00
0.00
estimate
-0.00
27
200
116
926
1.55
2.57
4.9
6.8
3.12
2.83
%
0.76
109
877
116
926
1.55
2.57
5.1
6.9
0.73
0.71
%
0.09
106
873
5
7
7.28
2.56
1.0
2.4
0.66
0.60
mmol/l
—
5
7
42
262
1.75
2.52
2.1
2.5
98.28
104.38
ug/g
0.04
32
209
85
639
1.55
2.44
3.5
3.6
32.90
50.93
mg/l
0.60
54
404
23
119
2.05
2.41
3.4
4.0
4.58
4.63
pmol/l
0.06
18
104
125
1025
1.53
2.38
5.3
3.9
0.11
0.00
estimate
0.49
27
187
104
820
1.52
2.38
2.1
2.0
104.50
98.24
pmol/l
0.49
52
392
23
121
2.01
2.31
1.4
1.3
—
—
—
0
0
115
931
1.51
2.30
5.2
6.9
8.97
8.70
%
0.57
108
887
116
941
1.51
2.30
4.9
6.8
55.14
57.31
%
1.16
109
903
8
23
3.57
2.29
1.5
1.1
—
—
—
0
0
123
1014
1.50
2.23
5.4
3.8
0.00
0.00
estimate
-0.00
26
200
5
9
5.66
2.22
2.4
1.9
—
—
—
0
0
86
660
1.51
2.20
4.3
4.2
3.72
9.21
mg/mmol
1.60
56
406
109
883
1.48
2.11
3.4
2.9
112.68
123.56
ug/l
0.26
99
834
107
866
1.47
2.07
7.7
9.5
1.10
1.16
inr
0.81
84
705
25
143
1.85
1.99
1.4
1.2
32.03
122.51
u/ml
3.13
12
51
74
560
1.49
1.99
4.7
3.2
2.13
0.00
estimate
0.50
24
161
40
263
1.64
1.98
2.5
3.4
3.81
6.77
e9/l
1.27
32
236
73
553
1.49
1.95
3.9
3.0
—
0.25
—
0
8
7
22
3.25
1.89
1.1
1.1
—
—
—
0
0
121
1017
1.44
1.85
5.2
6.9
0.04
0.04
e9/l
0.25
107
877
124
1050
1.43
1.80
5.4
7.2
0.20
0.19
e9/l
0.27
111
920
120
1011
1.43
1.78
5.3
6.9
0.56
0.57
e9/l
0.21
108
874
27
166
1.72
1.72
7.1
9.5
—
—
—
0
0
17
90
1.97
1.70
3.4
4.1
—
—
—
0
0
10
40
2.57
1.69
5.1
2.4
—
—
—
0
0
94
766
1.41
1.65
5.2
3.7
0.96
0.00
estimate
0.49
26
167
24
145
1.74
1.62
3.3
2.3
6.00
6.17
ph
0.39
17
89
208
2004
2.61
1.56
11.8
12.7
29.04
27.72
u/l
0.49
203
1959
38
263
1.54
1.53
1.5
1.6
1263.89
1225.82
nmol/l
0.09
26
192
120
1030
1.38
1.50
5.4
6.9
1.86
2.02
e9/l
0.54
111
911
28
181
1.63
1.49
2.5
2.2
0.00
0.00
estimate
—
6
42
9
38
2.43
1.47
1.2
1.2
—
—
—
0
0
42
300
1.50
1.47
3.7
2.8
1.17
2.61
e6/l
1.01
21
143
5
16
3.17
1.44
1.6
2.0
—
—
—
0
0
12
61
2.02
1.35
1.5
1.5
266.46
287.51
ug/g
—
7
36
49
368
1.43
1.33
1.7
1.7
469.72
460.77
pmol/l
0.06
40
322
191
1799
1.60
1.27
7.6
6.4
38.90
39.18
mmol/mol
0.19
179
1705
192
1811
1.61
1.26
5.3
4.4
1.40
1.31
mmol/l
0.95
173
1676
203
1943
1.95
1.26
16.2
13.3
—
—
—
0
0
121
1058
1.33
1.25
4.4
7.4
10.12
10.97
umol/l
0.79
110
1009
8
36
2.27
1.25
1.3
1.8
—
—
—
0
0
57
447
1.38
1.21
1.9
1.7
1.55
1.31
mg/l
0.14
37
347
14
79
1.83
1.20
4.1
6.5
0.84
0.89
%
0.22
14
70
127
1123
1.32
1.19
7.9
11.4
3.66
4.04
e9/l
1.65
113
981
99
848
1.31
1.16
1.9
2.0
1.49
1.40
mmol/l
0.32
78
711
27
188
1.50
1.08
3.0
4.0
7.39
7.39
ph
0.07
15
109
31
223
1.46
1.06
1.5
1.4
—
—
—
0
0
103
900
1.28
1.00
2.9
2.8
—
—
estimate
—
0
0
0
32
0.00
0.96
0.0
2.1
—
—
—
0
0
199
1912
1.62
0.95
6.8
6.0
2.87
2.77
mmol/l
0.85
185
1787
12
70
1.76
0.94
1.0
1.1
1.49
1.55
g/l
0.30
12
70
18
118
1.57
0.94
1.4
1.8
—
—
—
0
0
197
1893
1.54
0.88
6.2
5.3
4.75
4.70
mmol/l
0.28
182
1774
6
30
2.03
0.87
1.2
1.2
—
—
—
0
0
57
469
1.29
0.87
2.4
2.0
2.57
2.96
mg/l
0.67
47
412
12
72
1.71
0.87
1.0
1.1
0.95
0.91
g/l
0.28
12
72
35
268
1.37
0.87
1.4
1.5
—
—
—
0
0
30
224
1.39
0.86
1.3
1.5
—
—
—
0
0
73
621
1.27
0.86
2.5
2.4
—
—
—
0
0
8
45
1.81
0.85
2.3
1.9
144.25
130.00
g/l
—
8
34
6
31
1.96
0.85
1.2
1.3
—
—
—
0
0
55
452
1.29
0.85
5.0
3.9
1.02
1.02
kg/l
0.91
41
305
196
1884
1.51
0.84
6.4
5.2
1.43
1.46
mmol/l
0.71
181
1754
18
257
0.67
0.83
1.5
1.6
—
—
—
0
0
15
98
1.57
0.81
1.4
1.3
—
—
—
0
0
8
48
1.69
0.79
1.0
1.5
—
—
—
0
0
14
91
1.58
0.77
4.2
6.0
1.56
1.63
%
0.21
14
82
14
91
1.58
0.77
2.8
2.2
—
—
—
0
0
5
25
2.02
0.73
2.2
2.8
—
—
—
0
0
5
25
2.02
0.73
1.2
1.0
—
—
—
0
0
34
268
1.32
0.71
6.9
8.0
105.24
104.05
mmol/l
0.73
34
268
15
102
1.51
0.69
2.7
2.3
0.00
0.00
estimate
—
6
33
73
642
1.21
0.62
5.4
4.9
1.87
2.53
ug/l
0.56
68
576
5
30
1.68
0.62
1.2
3.0
4.36
4.83
e9/l
—
5
30
62
537
1.22
0.61
1.7
1.6
24.09
21.40
nmol/l
0.46
52
448
19
141
1.38
0.59
4.5
3.7
—
—
—
0
0
6
35
1.73
0.58
1.0
1.2
—
—
—
0
0
64
562
1.20
0.55
5.5
3.8
0.00
0.01
estimate
0.50
26
189
6
39
1.55
0.53
1.0
1.1
—
—
—
0
0
7
45
1.57
0.49
4.6
7.9
105.14
105.03
mmol/l
—
7
39
7
45
1.57
0.49
4.6
7.9
11.29
10.97
mmol/l
—
7
39
0
15
0.00
0.41
0.0
1.5
—
937.57
—
0
7
0
15
0.00
0.41
0.0
1.2
—
0.33
—
0
8
0
16
0.00
0.41
0.0
2.8
—
9.73
—
0
11
0
16
0.00
0.41
0.0
1.4
—
2.41
—
0
8
12
89
1.37
0.39
2.7
1.8
—
—
—
0
0
13
169
0.75
0.38
1.5
1.4
—
—
—
0
0
9
67
1.36
0.38
1.0
1.1
—
—
—
0
0
27
226
1.22
0.38
1.9
1.6
—
—
—
0
0
31
358
0.84
0.34
1.7
1.9
—
—
—
0
0
43
381
1.16
0.34
3.1
3.0
0.68
0.75
ug/l
0.45
27
226
6
46
1.31
0.33
1.2
2.9
60.33
58.12
%
—
6
46
86
804
1.12
0.30
2.9
3.1
—
—
—
0
0
14
112
1.27
0.29
3.4
5.7
—
—
—
0
0
28
245
1.16
0.26
1.5
1.3
—
—
—
0
0
42
380
1.13
0.25
2.8
3.7
157.60
440.42
ng/l
0.86
29
280
51
468
1.12
0.25
4.4
5.9
—
—
—
0
0
23
201
1.16
0.22
1.9
4.6
4.83
28.94
ug/l
0.60
16
168
20
173
1.17
0.22
3.7
5.7
0.20
0.57
%
—
5
60
0
11
0.00
0.21
0.0
2.9
—
0.73
—
0
11
0
10
0.00
0.21
0.0
3.1
—
529.20
—
0
5
0
12
0.00
0.21
0.0
2.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
14
117
1.21
0.21
8.7
9.7
17.31
16.25
%
0.62
14
110
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
2.8
—
700.17
—
0
6
0
14
0.00
0.20
0.0
1.6
—
68440.00
—
0
5
6
49
1.23
0.20
1.2
1.2
3.43
3.79
mmol/l
—
6
43
7
62
1.13
0.17
1.1
1.1
—
—
—
0
0
20
177
1.14
0.17
3.7
6.3
0.00
0.08
%
—
5
49
5
70
0.71
0.17
29.0
10.3
—
—
—
0
0
6
79
0.75
0.16
1.0
1.5
—
—
—
0
0
14
161
0.86
0.15
1.4
1.5
—
—
—
0
0
9
82
1.10
0.15
1.3
1.3
—
—
—
0
0
52
548
0.93
0.13
1.4
1.4
—
—
—
0
0
9
108
0.83
0.13
4.8
3.1
0.71
0.59
%
—
9
108
58
607
0.94
0.12
4.8
6.7
—
—
—
0
0
11
95
1.17
0.12
1.1
1.1
—
—
—
0
0
27
291
0.92
0.11
1.6
2.1
—
—
—
0
0
14
124
1.14
0.11
4.6
8.4
25.31
24.66
mmol/l
0.25
14
116
15
166
0.90
0.10
1.3
1.7
—
—
—
0
0
161
1632
0.94
0.10
19.8
19.5
334.83
332.81
g/l
2.14
161
1626
5
44
1.14
0.10
1.4
2.3
59.34
60.78
%
—
5
44
5
60
0.83
0.08
1.0
1.1
—
—
—
0
0
8
91
0.87
0.07
6.6
4.9
36.84
36.94
°c
—
8
91
52
509
1.03
0.03
4.7
4.5
—
—
—
0
0
20
201
0.99
0.00
10.7
9.7
95.00
96.03
%
0.26
20
194
21
209
1.01
0.00
1.2
1.5
—
—
—
0
0
22
219
1.01
0.00
10.0
9.3
5.36
5.20
kpa
0.23
22
209
22
219
1.01
0.00
10.0
9.4
7.39
7.41
ph
0.57
15
128
22
219
1.01
0.00
10.0
9.3
10.92
12.34
kpa
1.28
22
210
88
885
0.99
0.00
11.7
11.5
0.00
0.00
e9/l
0.58
73
719
20
195
1.03
0.00
9.9
9.7
127.10
123.61
g/l
0.31
20
189
13
128
1.02
0.00
1.2
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
0.02
—
0
6
0
6
0.00
0.00
0.0
6.8
—
—
—
0
0
0
6
0.00
0.00
0.0
5.5
—
12.56
—
0
6
0
6
0.00
0.00
0.0
1.0
—
53.33
—
0
6
0
6
0.00
0.00
0.0
6.0
—
24.83
—
0
6
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
8
83
0.96
-0.00
1.0
1.5
—
—
—
0
0
7
73
0.96
-0.00
1.1
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
28.50
—
0
8
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
8
83
0.96
-0.00
1.0
1.5
—
—
—
0
0
8
81
0.99
-0.00
1.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
2.14
—
0
5
0
7
0.00
-0.00
0.0
1.4
—
29.57
—
0
7
7
70
1.00
-0.00
2.3
2.3
81.00
287.90
ug/l
—
7
64
5
52
0.96
-0.00
1.6
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
5.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
8
83
0.96
-0.00
1.0
1.5
—
—
—
0
0
30
300
1.00
-0.00
1.4
1.6
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: E4_IDIOPATHIC_HYPERCALCIURIA – Idiopathic hypercalciuria

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).